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The  activity o f  prote in  k inase C (PK-C) has been imp l icated i n  regu lat ing 
the g rowth and diffe rent iat ion  of both no rmal and neoplastic hematopoiet ic 
cel ls .  We have examined the effects of the PK-C activators, phorbol  1 2 , 1 3-
d ibutyrate ,  mezere i n ,  and bryostat in  1, o n  t he p ro l i fe rat i o n  and l i neage 
commitment of en riched CD34+ human myeloid progenitor cel ls stimu lated by 
I L-3,  G M-CSF, stem ce l l  factor and the IL-3/GM-CSF hybrid cytok ine p 1XY32 1 . 
Coadmin ist rat ion of these PK-C activators with plateau concentrat ions of r 1 L-3 
or rGM-CSF i nduced 1 00-1 50% i ncrease in the nu mber of day 1 4  CFU-GM.with 
a selective st imu lat ion on neutroph i l  and macrophage l i neages wh i le  i n h i bit ing 
eosi noph i l ic  g rowth .  p lXY321 st imu lated an equivalent nu mber of CFU-GM,  
i nc lud i ng a predomi nant eos inoph i l ic  co mponent ,  when co mpared to the 
combinat io n  of saturat i ng  leve ls  of GM-CSF and I L-3 .  Bryostat i n  1 ,  when 
coadmi n istered wi th  p lXY32 1 (or  w i th  the combi nat ion of  I L-3 and G M-CSF) ,  
Xl 
se lectively enhanced the growth of neutrophil ic and monocytic l ineages whi le 
i nh ib it i ng eosi noph i l  development .  The i nh ibi t ion of eosi noph i l  colon ies by 
bryostat i n  1 was not m im icked by the coadmin istrat ion of rSCF,  rG-CSF or 
rCSF- 1  with p 1XY32 1 . Furthermore, neutral iz i ng ant ibodies to rG-CSF and 
rCS F- 1  fai led to b lock potent iat i on  of neutroph i l  o r  macrophage co lony 
format ion st imu lated by bryostatin 1 i n  conjunct ion wi th  p 1XY32 1 , suggesti ng 
that accessory cel l  effects are not sole ly respons ib le for th is  phenomenona. 
rSCF synerg i st ica l ly  e n hanced p l XY32 1 i nduced co lony format ion  by an 
ave rage of 1 44% by se lective ly st i m u lat i ng neutroph i l iC  and eos i noph i l ic 
g rowt h .  Coadmin i stratio n  of bryostat i n  1 with rSCF and p l XY32 1 further 
i ncreased co lony format ion by an average of 8 1  %. This combinat ion selectively 
st i m u lated ce l l s  of the macrophage l i neag e ,  and i n h i b i ted eos i n o p h i l  
d i ffere nt iat i o n .  H owever ,  b ryostat i n  1 i n h i bi ted e ryth ro id ( BF U - E )  and 
erythroid/mye loid mixed (CFU-GEMM) colonies i nduced by p lXY32 1 a lone or  i n  
combinat ion with rSCF. Together these resu lts i ndicate that 1 )  PK-C activ ity is 
i nvolved in  the g rowth and l i neage commitment of early and committed myeloid 
prog en i tor  ce l ls .  2 )  Pharmaco logic manipu lati on of PK-C may reg u late the 
g rowth and differentiat ion of  those ce l l s  exposed to early hematopoietic g rowth 
factors. This study raises the poss ib i l i ty that pharmacologic i ntervention at PK-C, 
i n  conjunction with hematopoietic growth factors ,  m ight be u sefu l in the ex vivo 
expansion of hematopoietic progen itor cel ls .  
I N T R O DU C T I O N  
literature Review of Hematopoiet ic G rowth Factors 
I. Hematopo iet ic  Hierarchy 
Al l  hematopoiet ic l i neages are derived fro m a sma l l  popu lat i on  of 
p luripotent stem cel ls (F ig .  1 ) . These stem ce l ls can either renew themselves to 
sustai n a p lu ri potent capacity, or g ive ri se to transit populat ions  of l i neage­
restricted progen itor ce l ls ,  wh ich i n  turn prol iferate and differentiate to produce 
the enormous steady-state supply of mature blood ce l ls .  Si nce the matu re blood 
ce l l s  of most types are re lat ively sho rt - l i ved,  hematopoies i s  is requ i red 
constantly even  in unstressed adu lt l i fe .  Althoug h ci rcu lat i ng levels of matu re 
blood ce l ls  are mai ntai ned with i n  narrow l im its of variat ion ,  l i neage-specif ic ce l l  
p roduct ion can be alte red rapidly i n  response to  various hematopoiet ic i nsu lts 
such as blood loss or acute in fect ion .  The regulat ion of  hematopoiesis resu lts 
f rom two overlappi ng and complementary control systems.  Stem cel l  surv ival 
depe nds on short range ,  cel l -ce l l  i nte ract ions  with the stromal ce l l s  of the 
hematopo iet ic  m icroenv i ron ment ,1 ,2 whereas the pro l i ferat ion  and terminal  
d i ffe re nt iat i o n  of  p roge n i to r  ce l l s depends cr i t i ca l ly on a network of  
hematopoietic g rowth factors (HG Fs).3 
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I I .  Bio logy of HGFs 
2 
HGFs compri se a fam i ly of g lycoprotei ns  with b io log ical specif ic i t ies 
defi ned by their abi l ity to support pro l ife rat ion  and different iation  of b lood ce l ls 
of different l i neages at d iffe rent stages of their matu rat ion .  The bioactivit ies of 
these factors are h igh ly complex and frequently overlappi ng .  On the bas is of 
their target cel ls ,  these g rowth factors can be classif ied i nto th ree g roups.4 The 
fi rst i ncludes factors that mai n ly affect early hematopoiet ic progen itors. These 
factors ,  adm in iste red alo ne ,  do not st i m u late colony g rowth .  I n stead ,  they 
exh ibit synerg ist ic effects when combi ned wi th other HGFs. These g rowth 
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factors are capable of mobi l iz ing early progen itors and stem cel ls i nto ce l l  cycle 
by shorten i ng the Go phase and regu lati ng the expression of the receptors for 
other g rowth factors. I nter leuki n - 1  ( I L- 1 ) , i nterleuki n-4 ( I L-4) and i nter leukin-6 
( I L-6) f i t  i nto th is group .  The second group i ncludes growth factors that affect a 
more committed progen itor populat ion which can give rise to more than one ce l l  
l i neage . I nter leuki n-3 ( I L-3) and granu locyte-macrophage colony-st imu lat ing 
factor  (GM-CSF) be long to th is  group .  I L-3 i nduces format ion  of  co lon ies 
composed of  e ryth roid ( in  the presence of e ryth ropo iet i n ) ,  g ranu locyte 
(eosinoph i l ,  basoph i l ,  neutroph i l ) ,  macrophage ,  mast cell and megakaryocytic 
e l e m e n t s .S I L-3 is a lso thought to be req u i red both fo r t he  co nt i nued 
prol i ferat ion  of hematopoiet ic mu lti potential cel ls6 and for the survial  of normal 
hematopoietic stem cells? GM-CSF is s im i lar to I L-3 except that it has no effect 
o n  mast ce l ls .S The th i rd g roup i ncludes cytok ines wh ich are l i neage specific. 
G ranu locyte colony-st imu lating factor (G -CSF) ,  macrophage colony-stimu lati ng 
factor (M-CSF or  CSF- 1 ) ,  i nterleuk in-5 ( I L-5) ,  and e rythropoietin (Epo)  affect the 
neutroph i l ic, monocytic, eosinophi l ic, and eryth roid l i neages respectively. 
Most recent ly ,  a nove l HGF, c-kit l igand or  stem ce l l  factor (SCF) has 
been cloned and its structu re e lucidated.8 ,g S imi lar to HGFs in the fi rst class, 
SCF has re latively litt le effect in vitro by itself, but synergizes strong ly with other 
HGFs to stimu late pro l i fe ration and d i fferentiation  in mu lt ip le l i neages i ncludi ng 
l ympho id  ce l ls . 1 0  In add i t ion, a membrane-bound form of SCF has been 
descri bed.g, 1 1 This fi nd ing suggests that SCF might also act at  the su rface of 
stromal ce l ls i n  regu lati ng the i nteract ion with hematopoietic stem ce l ls .  
The bio log ical effects of HGFs exh ibit two common features :  redundancy 
and pleiot ropy. More than one factor control ce l ls i n  any one l ineage ,  and most 
factors are act ive on cel ls of more than one l i neage .  For example ,  i n  in vitro 
culture system eosi noph i l  product ion can be sti mu lated, by th ree HGFs, I L-3, 
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GM-CSF, and I L-5,  but none of these factors is exclusively eosi noph i l  specific.5 
Howeve r, experi mental analys is of HGF effects may be compl icated by the 
heterogeneity of the bone marrow cel l  popu lation  i ntroduced in  cu lture and the 
variat ion of culture condit ions i n  different laboratories.  The secondarily re leased 
HGFs by residual accessory ce l ls  i n  cultu re may explain in part the lack of strict 
l i neage s pecif icity exh ibited by each of the HGFs . 1 2- 1 4  The observation  that 
anti-CSF-1  polyclonal  neutra l iz ing anti body o n ly b locks macrophage colony 
g rowth whi le exert i ng no effect on other types of colonies induced by I L-3/GM­
CSF fus ion prote in  supports th is  speculat ion (Fei Li , personal  observat ion ,  
1 992) . 
I I I. R eceptors for HG Fs 
L ike hormones ,  HGFs are extremely potent ,  and are usua l ly active at 
ng/ml concentrat ions .  Specif ic, h ig h-affi n ity receptors u nique fo r each type of 
HGF have been ident i fied on seve ral cel l  l i nes i nc luding normal hematopoiet ic 
ce l i s  and pr i mary myelo id leukemic ce l l s .  The ce l l u lar  d istr i but i on  of the  
receptors corresponds to the  known b io log ical specificit i es o f  each g rowth factor. 
Most hematopoietic progenitor cel ls have on ly a few hundred HGF receptors per 
ce l l .  Max imal  b io log ical responses can be i nduced when as few as 1 0% of 
recepto rs are occupied. 1 5  Some HGFs usual ly exh ibit additive or  superaddit ive 
i nteract ions with other HGFs. 1 0 
The recent c lon ing of many of the HGF receptors has faci l itated the study 
of the s ignal ing processes of HGFs.  Accord i ng to amino acid res idue sequence 
homology ,  H G F  receptors can be d iv ided i nto two fam i l i es .  One fami ly  i s  
characterized b y  having prote in  tyros ine ki nase activity a s  part o f  its cytoplasmic 
domain.  The ex and � PDGF receptor, the CSF-1 receptor (a product of the c-fms 
proto-oncogene) ,  and the SCF receptor (a product of the c-kit proto-oncogene) 
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are membe rs of the ty rosi ne ki nase receptor fami ly . 1 6 Low-affi n i ty b ind ing 
subunits for GM-CSF, IL-3,  I L-5, I L-4, I L-6, I L-7, erythropoietin ,  and G-CSF al l  
belong to a cytoki ne receptor superfami ly .  Th is fami ly also i ncludes receptors for 
g rowth hormone,  pro lact i n ,  c i l iary neu rotrophic factor, leukemia i nh ibitory factor, 
and the  proto-oncogene c_mpl. 1 7- 1 9  Al l  of these receptors have conserved 
amino acid sequence e lements (part icu larly fou r  cyste ine res idues and the 
sequence Trp-Ser-X-Trp-Ser with s im i lar spaci ngs)  in  t he i r  l igand -b ind ing 
ext race l l u lar domai ns . 20  One poss ib le reason for  the conservat ion of primary 
amino  acid sequence between these recepto rs i s  t hat i t  m ight reflect the 
i nteract ion of these receptors with other ce l l  surface mo lecu les t hat are involved 
in receptor b i nd i ng  aff in ity and s ig nal  transduct io n .  When  expressed on  
non  hematopo iet ic ce l l s ,  most of  these receptors d i sp lay o n ly l ow  aff i n i ty 
b i nd ing . 2 1  Recently several i nvest igators have identif ied a human cel l  surface 
peptide subun i t ,  KH97 W subun i t), which acts as a common component for 
mu lt ip le g rowth factor receptors, i ncluding those for I L-3, G M-CSF, and IL-5,  and 
is  associated with t ransmembrane s ig nal  t ransduct ion process. 2 1  Al thoug h 
isolated KH97 does not b ind to e i ther of those g rowth factors ,  coexpression of  
KH97 wi th  each low affi n ity b ind ing chai n (ex subun it )  fo r GM-CSF, I L-3 o r  I L-5 
gave rise to high aff in ity recepto rs. 22 The f i nd ing that the human I L-3, I L-5 and 
GM-CSF high affi nity receptors each has its own l igand speci fic ex subun i t  but 
shares a common � subunit may we l l  explai n the high and low affin ity forms of 
HGF receptors and also provides a mo lecular bas is  for  part ia l ly competit ive 
cross-bindi ng between IL-3 and GM-CSF in  some hematopoietic cel ls .  2 1 ,23,24 
This model is also cons istent with the observat ion that these H G Fs i nduce 
s i m i lar i nt race l lu lar  s igna ls  and have overlappi ng b io logical act iv i t ies .  The 
b i nd i ng  of  H G Fs to the i r  rece ptors i s  accompan ied by rap id receptor  
downreg u lat ion ,  i nternal izat ion of the  l igand-receptor complex and subsequent 
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destruction of the HGFs as wel l  as the recycling of recepto r to the ce l l  su rface.25 
There is no consensus on whether the i nternal izat ion process is required for 
t ran s m e m b rane sig na l i n g . 26 ,2 7  One recent pub l icat ion  suggests G M-CSF 
recepto r i nternalizat ion i s  not requ i red for tyros ine  phosphorylat ion i nduced by 
G M-CSF bind i ng28 B i nd ing of a specif ic HGF to its receptor can also induce 
downregu lat ion  of recepto rs for other HGFs ,  a phenomenon  termed trans­
downmodu lation .  The relative act iv it ies among IL-3, GM-CSF and CSF- 1 fol low 
a distinct h ie rarchy .  For  example,  I L-3 can downregu late G M-CSF and CSF- 1 
receptors whereas G M-CSF and CSF-1 have no effect in downregu lat ing IL-3 
receptors . 1 5 The ro le of trans-downmodu lati on process in s ignal t ransduct ion is 
also u nclear. 29 
IV. B ioactivit ies of HG Fs 
Si nce seven dist inct hu man HG Fs ( I L-3, G M-CSF, G-CSF,  CSF- 1 , I L-5 ,  
p lXY321 and SCF) are i nvo lved i n  th is  study, the fo l lowi ng review wi l l  focus on 
these HGFs .  
I L- 3  I L-3  i s  pr imar i ly an act i vated T lymphocyte-der ived m u ltipotent ia l  
hematopoiet ic g rowth factor.4 In  add it io n  to act ivated T cel ls, other cel l  types 
such as hu man thymic epithe l ia l  ce l l s , 3D mur ine  mye lomonocytic  ce l l  l i ne ,  
W E H I , 3 1  act ivated m u ri n e  mast ce l l s ,32,33 and  murine ke rat i nocytes 34 also 
express IL-3. 
To date,  genomic and cDNA clones for muri ne ,  g i bbon ,  and human I L-3 
gene  have been iso lated.35,36 The gene for I L-3 has been mapped to human 
chromosome 5 and murine chromosome 1 1 ,  closely l i nked to the genes for  I L-4, 
I L-5, CSF- 1 , c-fms (CSF- 1 receptor), and GM-CSF.4 cDNAs for both murine and 
hu man I L-3 e ncode precursor protei ns with s ignal  peptides that are cleaved to 
form mature prote ins  with mu lt ip le g lycosylat ion sites and an essent ial d isu lf ide 
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bond. The molecu lar weight of IL-3 is 25 kDa for human and 28 kDa fo r murine .  
At the amino acid sequence level ,  there is on ly 29% homology between the 
muri ne and hu man I L-3. Consistent with th is  lack of homology, the prote i ns are 
species-specific i n  thei r act ions.37 Like most HGFs, the nonglycosy lated form of 
I L-3 is active in vitro although it is heav i ly  N-g lycosylated i n  its natu ral secreted 
status .38 This property offers a great advantage i n  large scale b ioengi neering 
production  of such factors s i nce bio logical ly active I L-3 can be produced from 
prokaryotic expression systems wh ich lack eukaryotic g lycosylation  mach inery .  
I n  both the muri ne and human systems, i t  has been shown that I L-3 alone, 
or synerg i stical ly with other early act ing he matopo iet ic g rowth factors, i ncluding 
I L- 1 , I L-6 ,  SCF, and G-CSF ,  suppo rts the pro l i fe rat i on  of mu lt i potentia l  
progen itors on ly at the  early stages o f  the i r  development.39. 40 Addit ional l i neage 
restricted factors such as GM-CSF, IL-5 , CSF- 1 and erythropoiet i n  are requ i red 
for  the term ina l  d i fferent iat i on  of these I L-3- i nduced proge n itors . 4 1 -43 I n  the 
murine system , it has been shown that the in  vitro IL-3-i nduced progenitors can ,  
g iven seco ndary cytok ine s igna ls ,  d i ffe rent iate i nto myelo id- l i neage as  we l l  as 
lymphoid- l i neage cel ls in vitro44 
G M-CSF GM-CSF i s  produced by a variety of ce l l  types i nc lud ing T cel is ,  B 
celis, macrophages,  mast cel is ,  endothel ia l  cel ls and fi brob lasts i n  response to 
cytok ine  o r  i mm u ne and i n f lam matory st i m u l i  such as an t ige n ,  lect i n ,  
l i popolysaccharide (LPS) ,  tumor necrosis factor (TNF) ,  and I L- 1 . cDNAs for both 
muri n e  and human GM-CSF encode precu rsor prote i ns  with a 1 7  am ino  acid 
sig nal peptide that i s  cleaved to fo rm mature muri ne and hu man prote ins  with 
1 24 and 1 27 am ino  acids ,  respect ive ly .  Despite the prese nce of mu lt ip le 
g lycosy lat ion sites,  the carbohydrate moiet ies do not appear to be i m po rtant for 
the in vitro and in vivo funct ions of GM-CSF tested to date.45 Althoug h human 
GM-CSF is  54% homologous to its muri ne counte rpart at  the amino acid leve l ,  
the two prote ins are species-specific in their act ions .  
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Although GM-CSF was i n iti al ly characterized by its abi l i ty to stimu late 
neutroph i l ,  monocyte/macrophage,  eosi noph i l  and basoph i l  colony fo rmation ,  i t  
has s i nce been shown that it has additi onal functions on  hematopoietic, as wel l  
as n o n hematopoietic ce l ls . 1 5. 45 . 46 The in vitro prol iferative actions of GM-CSF 
are not l im i ted to the g ranu locyte and macrophage progenitors but also i nclude 
erythroid and megakaryocyte progen itor cel ls. In mature hematopoietic ce l ls ,  
G M-CSF e nhances the functi ons  of the di fferent iated ce l l s  and thus can 1 )  
pro long the s u rvival of matu re neutroph i l s  and eosi noph i l s ;  2 )  e n hance the 
ab i l i ty of  the neutroph i l s  and eosi noph i l s  to respond to seco ndary sti mu l i  
resu lti ng  i n  i ncreased su perox ide producti o n ,  leukotri e n e  synthes is ,  and  
arachidon ic acid re laease ; 3 )  enhance the abi l ity of neutroph i ls ,  eosi noph i ls ,  
and macrophages to phagocyt ize; 4)  i ncrease the ant i body-dependent  cel l ­
mediated cytotox icity of neutroph i l s ,  eos i noph i ls and macrophages towards 
tu mor  ce l l s ;  and i nduce the synthes is and release of  a n umber of  cytoki ne ,  
i ncludi ng I L- 1  and TNFa from monocytes.  Among non-hematopoietic ce l ls ,  GM­
CSF can i nduce hu man endothe l i a l ce l ls  to m i g rate and pro l i ferate . 47 I n  
addition ,  GM-CSF can also st imu late the pro l i feratio n  o f  a number o f  tumor ce l l  
l i nes ,  i nc lud ing osteogen ic  sarcoma , smal l cel l  carc inoma of l ung  , b reast 
carcinoma and co lon adenocarci noma ce l l  l i nes.45 
G M-CSF/I L-3 hybr ik ine (p1XY321) I n  exami n i ng  the cross-reactiv i ty of G M­
CSF and IL-3 with the ir  receptors and possible mechan isms of synerg ism,  fusion 
prote ins  contai n i ng both GM-CSF and I L-3 domai ns  have been developed 
through DNA recombi nant techniques in recent years. Among those hybrik i nes 
p l XY32 1 s howed e n hanced hematopoi eti c sti mu lat i ng  activity as wel l  as 
receptor  affi n ity to target cel ls compared to e ither I L-3 or  G M-CSF.  p l XY32 1 
hasalso been shown to be more potent than an equi molar m i xture of G M-CSF 
and I L-3 i n  stimu lat ing co lony formati on by hu man bone marrow cel ls .48.49 One 
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recent com m u n icat ion demonst rated that p l XY321 effect ive ly synerg izes with 
SCF to sti m u late bone marrow reconst i tut i on  in S C I D  m ice with h u man 
hematopoietic stem ce l ls ,50 and another reported synerg istic st imu lat i on  of early 
h u m a n  h e m atopo iet ic  p rogen ito rs. 5 1  A lthough sti l l  in early cl i n ical testi ng ,  
p lXY32 1 may prove to  be  one o f  the fi rst generation  of mo lecu lar eng i neered 
HGFs exh ibit i ng  potential therapeutical value. 
G-CSF G-CSF exerts i ts specific effects on  the pro l i feration ,  d i ffe rentiation ,  and 
act ivat ion  of  h ematopo iet ic ce l ls  o f  the neutroph i l i c  g ranu locyte l i neag e .  
Recently i t  was reported that G-CSF is a n  early-act ing factor that can e nhance 
t he  prol i fe rat ion  of mu lt i  potent ia l  hematopo iet ic  ste m  ce l ls  and support the  
formatio n  of b last co lon ies in  vitro and CFU-S in vivO.52 G-CSF is  produced 
mai n ly by monocytes and macrophages upon activat ion by endotoxi n ,  TN Fa and 
I FNy. Other  cel l  types i nclud i ng f ibrob lasts , endothel ia l  ce l ls ,  and bone marrow 
stromal  cel ls  can also secrete G-CSF after LPS, IL - 1  or TNFa activation .  I n  
addit i on ,  var ious carci noma ce l l  l i nes and myelob last ic leuke m i a  cel ls  can 
express G-CSF constitut ively. 1 5, 46, 53 
In h umans,  two d isti nct cDNA clones for G-CSF, encod ing  207 and 204 
am ino  acid precursor prote i ns ,  have been iso lated. Both prote i ns  have a 30 
amino acid s ignal  peptide and have identical amino acid sequences except for a 
th ree amino acid i nsert ion (de leti on )  at the 35th amino acid residue from the N­
term inus of the mature prote i n. Compared to othe r cytok ines ,  G-CSF shares  
sign if icant am ino  acid seque nce homology w i th  I L-6 .  Human G-CSF is  73% 
homologous at the amino acid leve l to muri ne  G-CSF and the two prote i ns  show 
species cross- reactivity. 53 
CSF-1 CSF- 1 , alternately known as M-CSF, can st i mu late the format ion of 
macrophage  co lon ies from bone marrow hematopoiet ic prog en i tor  ce l ls .  I n  
mature macrophages,  CSF- 1  i s  fou nd t o  e n h ance macrophage ant ibody-
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dependent ce l l -mediated cytotoxicity and to pri me and potentiate macrophages 
in thei r abi l ity to ki l l  tumor ce l ls and microorganisms. It i s  now known that CSF-1 
can be produced by a nu mber  of  cel ls ,  i nc lud i n g  f i b ro blasts ,  activated 
macrophages ,  secreto ry ep i the l ia l  ce l ls of  the endometri u m ,  bone marrow 
stroma l  ce l l s ,  and LPS- or  cytok i ne -activated e ndothe l ia l  ce l l s . 5 4  The 
m e m b rane-bou nd CSF-1  when expressed in a fi broblast mono layer  can 
mediate the adhesion and pro l i ferati on of macrophages expressi ng the CSF-1 
receptor. 55 Although there is 80% homology between the human and murine 
CSF- 1 , mCSF-1  is species-specif ic i n  i ts  actions  whereas human CSF-1  is 
active i n  the murine system .  
I L-5 Murine  I L-5 was o rig i na l ly  di scovered as a so lub le T cel l-derived factor, 
wh ich  promotes the p ro l i fe rat ion  and d i ffe re ntiatio n  of  B lymphocyte and 
eosinoph i ls .  H u man I L-5 i s  a potent eosi noph i l  d i fferent iati o n  and activation  
factor ,  but  was  reported to have l i tt le  o r  n o  activ i ty toward hu m an B 
lymphocytes .56 Recently, I L-5 was also shown to affect basoph i l  d ifferentiation  
and function ,  suggest ing I L-5 mig ht have a ro le i n  the  pathogen ic i nf lammatory 
res p o n s e s  i n  h y pe rse n s i t i v i t yS7 -59  Muri n e  and hu man I L-5 are 70% 
h o mo logous  in t h e i r  a m i n o  acid seque nce and have spec ies c ross­
reactivity. 60 ,6 1  The observation  of a secreted forms of human and muri ne  I L-5 
receptor a suggests a possible in vivo regu lato ry ro le by the secreted form of 
HGF receptor(s) .62 
SCF This newly identifi ed ple iotropic cytoki ne has various ly been termed c-kit 
l i gand (KL) , stem cel l  factor (SCF) ,  mast cel l  g rowth facotr (MGF) ,  and steel­
facto r (SLF) .  A mo lecular c lon ing  study i so lated two forms of SCF.  One is  
so lub le ,  w h i le t he  othe r  i s  membrane-bo u n d .9 . 1 1  The so lub le form i s  a 
proteolytic cleavage product of the t ransmembrane form. Both the soluble and 
the transmembrane form of SCF have g rowth factor activ it ies. However, s ince 
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mouse mutat ions  (S id) capable of e ncod ing on ly  the soluble t ru ncated form of 
SCF, lacki ng both the t ransmembrane and cytoplasm ic  domains ,  e x h i bi t  
phenotypic defects almost ident ical to those mutat ions i n  wh ich no  SCF protei n 
i s  p roduced, the  membrane bound form is  l ike ly  to be i mportant i n  mediat ing 
cel l-ce l l  adhesion and i nteract ion and must have a critical b io log ical ro le i n  the 
i ntact o rgan ism. 1 1 ,63- 66 Mur ine or rat SCF i s  h ig h ly homologous to human SCF 
(80%).  Whereas both rat and mouse SCF are active on  human ce l ls ,  the human 
protei n  is 800 fold less active on mouse or rat ce l ls .8 
SCF has  b i o log ica l  act iv i t i es i n  t h ree  type o f  ce l l s  i nc l u d i n g  
m e lanocytes , 67 primordia l  germ cel ls 65 a n d  hematopoietic progen itor  ce l ls  
duri ng embryon ic development 68 and postnatal l i fe .  Another  i ntri gu ing fi nd ing 
i s  t hat SCF is also expressed i n  the nervous system,  suggest ing SCF may act 
as a g rowth factor  i n  t h i s  syste m as we l 1 . 69 ,7 0 On  p u ri f i ed pr i m i t ive  
hematopoiet ic precu rsors from muri ne and hu man bone marrow, SCF acts i n  a 
synerg i st ic manner  with various growth  factors ,  such as IL- 1 , I L-3, I L-7, GM­
CSF, G-CSF, CSF- 1 , and eryth ropoiet in  (Epo) to i nduce myeloid, e ryth roid and 
l ymphoid  m u lt i - l i neage co lony  format ion 7 1 -74 One recent  com m u n icat ion  
demonst rated that SCF e nhanced GM-CSF/ I L-3 fus ion protei n's stim u lati ng 
effect o n  bone marrow reconstitut ion of  SC I D  mice by h u man bone marrow 
stem ce l ls .  I n  th is  study, mature human ce l ls of myeloid, lymphoid and eryth roid 
l i neages have been found in SC ID m ice blood fo l lowi ng t reatment with SCF 
and G M-CSF/ I L-3 fusion protei n . 50 I n  another study i nvolv i ng long term cu ltu res 
of CD34+, D R- ,  CD1 5- ,  rhodamine du l l bone marrow cel l  popu lat ion (potent ial  
stem ce l ls ) ,  SCF was found to synerg ize with I L-3/G M-CSF fusion prote i n to 
enhance the mu lt i l i neage blood ce l l  product ion and to stimu late and expand the 
h i g h - pro l i fe rat ive pote nt ia l  co lo ny- fo rmi ng  ce l l  popu lat i o n  ( H P P-CFC,  a 
potent ial stem cel l popu lation ) .  It fai led, however, to prolong the duration  of long 
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term bone marrow cu ltu re ,  a parameter considered to be a measure of stem ce l l  
se l f - re newal ,  to  a g reate r extent than that ach ieved by any other  g rowth 
factor(s ) ,  e ither alone or in combi nat ion 5 1  Th is  f ind ing i ndicates that there are 
l ike ly other  un identified factor(s) or condit ions i nvolved i n  the regu lation  of stem 
ce l l  survival and self-renewal. 
V. C l i n ica l App l icat ions  
Extensive cl i n ical trials have bee n undertaken with both GM-CSF and  G­
CSF for the treatment of various congen ital and di sease- or chemotherapy­
i nduced neutropen ias and/or pancytopen ias.  Rece ntly, G M-CSF and G-CSF 
have received FDA-approval for use i n  autologous bone marrow transplantation 
and chemotherapy- i nduced neutropen ia. Cl i n ical trials for IL-3, CSF-1 , p lXY321 , 
and SCF are cu rrently underway to eva luate thei r potential ro le i n  the treatment 
of cancer, fungal i nfect ions and various bone marrow fai lu re states.lO Recently , 
sev e ra l  reports ( i nc lud ing  one fata l case) descri bed the deve lopment of  
eosi noph i l ia  i n  patients fol lowing admin istration of  GM-CSF or  IL_3? 5- 80 I n  some 
cases eosi noph i l i a  i nduced by GM-CSF resu lted in severe pu lmonary and 
myocardial  i nfi ltrat ions which either forced the cessati on of admin istrat ion 78 or 
resu lted i n  fatal tox ici ty . 75 I n  v iew of the fact that G M-CSF and I L-3 are also 
potent in sti mu lat ing eosi noph i l  development and activation  in vitro,6,43.81-84 i t 
would be i m portant to develop pharmaco logic approaches to modu late or block 
this process. 
VI. S igna l  Transduction of HG Fs 
In the past decade , the i n format ion re lati ng mo lecu lar events that take 
p lace wit h i n  hematopo ie t ic ce l ls  fo l lowing exposure to g rowth facto rs i s  
accu mu lati ng at  an  unprecedented pace. I t  i s  obv ious that e lucidatio n  of these 
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mechanisms wi l l  offer new pharmacolog ical approaches fo r the treat ment of a 
wide variety of hematopoietic disorders as wel l  as cancer therapy. The fol lowi ng 
is a brief rev iew of i n format ion avai lable today about the s igna l  transduc ing 
mechanisms of  HGFs. 
Transmembrane Sig na l i ng of HG Fs It is  wel l  known that H G Fs exert thei r 
effects by b ind ing to receptors o n  hematopoietic cel ls .  Like other g rowth factors 
or  hormones, once HGFs have bound to their  receptors, the s ignal must fi rst be 
t ransduced across the cel l  membrane. Cu rrent ly, three major  mechan isms for 
accompl ish ing th is are known . 
F i rst, b ind ing of the factor may i nduce activat ion  of an i ntri ns ic receptor 
tyros i ne  ki nase act ivity such as the CSF- 1 and SCF receptors .  Subsequent 
phosphory lation  of cytosol ic and membrane-associated prote ins  e ither v ia di rect 
or i ndi rect mechan ism,  may then transmit the i nformational content of the g rowth 
factor i ntrace l lu lar ly .  Those substrate protei ns  i nc lude ce l l  su rface recepto rs 
(auto-phosphory latio n ) ,  phosphatidy l i nositol ( P I )-3 ki nase,85 ,86 phospho l ipase 
C y  (PLCy) , 86- 88 the c-ra f  seri ne/t h reo n i n e  ki nase , 89- 9 1  and t he  GTPase-
activat ing prote i n (GAp) .85,90 
Alternatively, for non-tyros ine ki nase HGF receptors such as G M-CSF and 
IL-3, l igand b ind ing may i nduce al losteric changes that al low i nd i rect stimu lat ion 
of  phosphol ipase C (PLC) or adenylate cyclase and the consequent product ion 
of i nt race l l u lar second messe ngers .  The e levated 1 , 2 d iacy lg lyce ro l (OG )  
turnover, possib ly v i a  PLC- med iated phosphatidylcho l i ne  (PC) hydrolysis ,  has 
been found  in bone marrow macrophages in response to both GM-CSF and IL-
3.92 I n  th is  system the ro le of G prote ins i n  coup l ing the s ignal from receptor to 
PLC is  controversial . 29 Other evidence suggesti ng a ro le for PLC in HGF act ion 
comes from the  f ind ings that exogenous ,  nonspecif ic PLC i s  itself a weak 
m i toge n  for bone- marrow-de rived macrophages and e l i c its a vari ety of 
responses com mon to CSF- 1 , GM-CSF and I L_3. 93, 94 
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Last ly ,  It has also been observed i n  several  cases that recepto rs 
complexed with g rowth factors are i nternal ized. Fol lowi ng i nternal isat ion,  either 
the g rowth factor or  the receptor may be i nvo lved i n  fu rther s ignal transduction .29 
Prote i n P h o s p h otransferases (p rote in  ki nases) i n  HG F S i g n a l i n g  
Prote i n  phosphory lation  p lays a n  i mportant role i n  regu lati ng the act iv ities of 
many key e nzymes and other  prote i ns respons ib le  for h ematopoietic ce l l  
p ro l ife ratio n ,  d i fferent iat ion  and fu nct ional  act ivat ion  i n  response to H G Fs. At 
least th ree major phosphotransfe rase systems appear to be i nvo lved at some 
l e v e l  i n  t h o se proce sses .  These  a re t h e  ty ros i n e  k i nases ,  t h e  
Ca2+/phosph o l i pid-depe ndent p rote i n ki nase C (PK-C) ,  and t h e  cAMP­
dependent prote i n  ki nase A (PK_A) . 27 And the l ist conti n ues to expand,  as 
exemplif ied by the case of c-rafki nase. 29 
Although GM-CSF, IL-3 and G-CSF receptors do not possess a tyrosine 
k inase domain ,  these HGFs can i nduce the rapid tyrosi ne phosphory lation  of a 
variety of ce l lu lar  prote i ns  i n  a number  of cel l  types.95_ 1 0 1  One observat ion  
suggesti ng a reg u latory ro le for tyrosi ne phosphory lat i o n  i n  the pro l i ferative 
response to such HGFs comes from the f i nd ings  that the prote i n  ty ros i ne  
phosphatase i n h i bitor, vanadate , wh ich enhances tyros i ne  phosphorylatio n  i n  
response to G M-CSF or IL-3 i n  a factor-dependent ce l l  l i ne ,  a lso e nhances the 
prol iferative response to these HGF S.1 02 I n addit ion , i ntroduction  and expression 
of non recepto r tyrosi ne k inase oncogenes,  such as v-src or  v-ab/, i nto HGF­
dependent ce l l  l i n e s  i nduces factor  indepe nde nce v i a  a n o n autocri n e  
mecha n i s m . 1 03, 1 04 Thus far, the ro le of tyrosi ne phosphorylat ion  i nduced by 
G M- C S F  o r  I L-3  i n  t h e  g rowt h and l i neage co m m it m e nt o f  n o rma l  
hematopopietic progen itor cel ls i s  not known. 
cAMP-dependent prote in  kinases (PK-A) ,  wh ich mediate the second 
messenger funct ion of cAMP,  have also been imp l icated in modu lat ion of g rowth 
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factor action .  CSF- 1 and G M-CSF i nh ibit cAMP accumu lat ion i n  macrophage or  
neutroph i ls ,  perhaps by  i n h ib i t ing adenylate cyclase and/o r increasi ng  cAMP 
phosphodiesterase act iv it ies. 1 05 , 1 06 I n  addit ion ,  G-CSF can stimu late adenylate 
cyclase and induce a rapid and transient i ncrease of cAMP i n  muri ne myeloid 
ce l l  l ine, NFS-60 ce l ls . 1 07 I n  other systems, e levat ion of cAMP has been shown 
to enhance I L-3- i nduced megakaryocyte and e ryth ro id colony format ion and 
i n h i bi t  g ranu locyte co lony format i o n  and H G F-st i mu lated macrophage 
pro l i ferat ion . 1 05 , 1 08 , 1 09 
PK-C S igna l i ng  Pathway and PK-C Activators. PK-C was fi rst ident i f ied 
as a proteo lytical ly activated protein ki nase present in may t issues in 1 977. 1 1 0 
The p ivotal ro le of PK-C i n  s ig nal transduct ion  and tu mor  promot ion was not 
known u nt i l  1 984. 1 1 1  Si nce then the i n formation  of th is  enzyme has expanded 
explos ively ,  and d iverse ro les of th is  enzyme i n  the g rowth  control and cel l  
differentiat ion are wel l  estab l ished in ce l ls of many types. To date PK-C is  found 
to cons ist a large fam i ly of mu lt ip le subspecies, with closely re lated structures 
that exh ib it  subtly d i fferent properties. The heterogeneity and d i fferential ce l lu lar 
expression of th is  enzyme has been a major focus of b iomedical research. 1 1 2  
Phorbol esters (Fig . 2 ) ,  a g roup of  natu ral products derived from Croton 
tiglium, also a class of potent tumor promoters, e l icit a wide variety of responses 
that are very s im i lar  to those of hormones and g rowth factors .  A ser ies of 
subsequent studies in several labo rator ies has identif ied PK-C as the pri mary 
site of act ion for the phorbol esters. Specifically, these agents m im ic the action of 
DG and b ind and activate PK-C direct ly on the cel l  surface . 1 1 3, 1 1 4 This fi nding 
suggests that the phorbol esters act through one of the major  s ignal transduction 
pathways with in  ce l ls .  The stability and g reate r potency of phorbol esters make 
them a standard pharmcolog ical probe i n  pertu rb ing  the PK-C s igna l  
pathway and,  due to the ir  applicat ions in  many f ie lds,  the theoretical 
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concept of PK-C has s i nce evo lved sign ificantly. 
Although it i s  we l l  establ ished that PK-C is the pri mary site of act ion for 
phorbol este rs, the bio logical responses i nduced by th is  agent i ndicate that al l of 
its act iv i t ies can not be explai ned by a s ing le ,  homogeneous class of receptors. 
For example,  phorbol 1 2-myristate 1 3-acetate ( PMA) and the related diterpene 
mezere in  (Fig . 3) are s im i lar in i nf lammatory potency. I n  contrast, PMA is much 
m o re pote nt  in t u m o r  promot i o n  than mezere i n .  Fu rt h e rmore ,  d i ffe ren t  
concentrat ions  of the same co mpound may be requ i red to i nduce d i fferent 
responses .  It is curre ntly not clear whether  th i s  behav i o r  i s  re lated to the  
heterogeneity o f  PK-C or other non-PK-C mediated events. 1 1 4 
Another u n ique aspect of PK-C activators re lates to the i r  dual act ions. It 
has been fou nd in various ce l l  systems that ,  u n l i ke a short- l ived DG, P K-C 
act ivators i n it ia l ly act ivate PK-C,  whereas susta ined exposure i nduces the  
deg radat ion  of the PK_C. 1 1 2 Th is  property has i mportant i m p l icat ions  w i th  
respect to  the k inetic or schedu le coordi nat ion o f  the  use o f  th is  class of agents 
with other  compounds, such as g rowth factors. 
Although phorbol esters have been most com mon ly ut i l ized for the d i rect 
man ipu lat ion  of PK-C, the i r  tumor promot ing act iv ity makes them unsu itable for 
c l in ical use. Recently, a new class of PK-C activat ing compounds with no tumor 
pro moti ng propert ies,  the bryostat ins ,  has been identif ied. 1 1 5, 1 1 6  The bryostati ns 
represent a g roup of macrocycl ic lactones (F ig .  4) extracted and chemical ly 
puri fied fro m  the mari ne bryozoan , Bugu/a neritina. 1 1 7  Although  PK-C activat ing 
bryostat i n  analogs such as bryostatin 1 m imic many phorbol ester effects, they 
block those phorbo l este r mediated events which they do not i nduce, i nc lud ing 
tumor pro motion  in mouse ski n 1 1 8 , 1 1 9 and i nduct ion  of diffe rent iat ion in  some 
H L-60 sub l i nes . 1 20 The bryostat ins have been shown to exert ant ipro l i fe rative 
effects toward diverse neoplastic ce l l  l i nes i ncluding melanoma, renal ce l l  
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carc inoma ,  and some leukem ias ,  and agai nst pri mary cu ltu re of hu man 
leuke mic myelob last. 1 20 - 1 22 The potential c l i n ical use of bryostati ns  as anti­
neoplastic agents is currently being evaluated in phase I tria ls .  In addition  to its 
possib le ro le as an anti leukemic agent, bryostat in 1 has proven to be a valuable 
tool in prob ing the mechanism by which signal transductio n  events are i nvo lved 
in the regu lation  of hu man hematopo iesi s . 1 23- 1 26 
The cu rrent u nderstand i ng of transmembrane s igna l i ng of hormones ,  
n e u rotransmitters , and g rowth factors ho lds that b i nd i ng of a l igand to its 
receptor resu lts in ce l l  membrane phosphatidy l i nositol 4 , 5-bisphosphate (P IP2)  
b reakdown and formati on  of hydro lytic products, such as 1 , 2-d iacyl-g lycero l 
( DG)  and i nositol 1 ,4 ,5-trisphosphate ( I P3 )  (F ig .  5 ) .  The former activates the 
seri n e/th reon i ne k i nase, p rote i n  ki nase C (PK-C) ,  and the latter  i ncreases 
i ntrace l lu lar calci u m  concentrati ons . 1 27, 1 28 Other pathways also ex ist capable 
of generati ng DG without P IP2 hydro lysis. For example, plate let derived g rowth 
factor (PDGF) ,  CSF- 1 , GM-CSF and I L-3 have been shown to en hance DG 
turnover possibly v ia phosphatidylcho l i ne  hyd rolysis without affecti ng I P3 level 
upon their b ind ing with receptors. 27, 29 
PK-C and Hematopoies isAs prev ious ly demonstrated in ce l l s  of var ious 
tissue types, PK-C has been i mpl icated i n  regu lati ng the actions of certain HGFs 
in cel ls of h ematopo ietic orig i n .  CSF- 1 , GM-CSF, and IL-3 have been reported 
to i nduce a translocation and/or activat ion of PK-C i n  a number of hematopoietic 
cel l  types, wh ich corre late with pro l i ferative activ it ies.99, 1 29- 1 32 Several l i nes of 
evidence suggest that the action  of HGFs may be i nf luenced by protei n  k inase 
C (PK-C) activity. For example, the PK-C stimu lati ng phorbol ester, TPA ( 1 2-0-
tetradecanoy lphorbol- 1 3-acetate) is capable of serv i ng as a source of colony 
stimu lating activity for mur ine myelo id hematopoietic progen itors in vitro, 1 33- 1 37 
and promotes the survival and pro l iferation of I L-3 dependent ce l l  l ines. 1 38 
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Figu re 5. PK-C sig nal ing pathway and dua l  act ion of  PK-C activators .  
I P3 i ndicates i nositol 1 ,4 , 5-trisphosphate ; DG, d iacylg lycero l ;  G ,  G prote ins ;  
PLC,  phosphol ipase C.  
Agents with PK-C i n h i b i tory act iv ity have a lso been fou nd to i n h i bi t  in  vitro 
c o l o n y  fo rmati o n  by hu man bone marrow ce l l s  exposed to g ra n u locyte­
macrophage colony sti mu lat ing factor (G M-CSF) and i nterleuki n-3 ( I L_3) . 1 39 In 
addit i on ,  PK-C act iv ity has been i mp l icated in reg u lat i n g  the g rowth and 
d i fferentiati on  of human and murine leukemic ce l l  l i nes. 1 40 , 1 4 1  One recent study 
using the  human megakaryob lastic leukemia ce l l  l i ne ,  M07, which prol iferates i n  
response t o  either human GM-CSF or  IL-3, PMA or  bryostati n  1 was shown to 
i n h i bi t  the g rowth and tyrosi ne phosphorylat ion of several substrates i nduced by 
t hese two g rowt h  factors.  There was no alte rat i on  of G M-CSF receptor  
expression or  affi n ity. Pretreati ng the ce l ls  w i th  the protei n  tyros ine phosphatase 
i n h i bi tor  vanadate part i a l ly  reve rsed the  i n h i b i to ry effects of PMA.  Th i s  
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observat ion suggests that PK-C act iv ity may also have profound effect i n  
modu lat i ng o the r  s i gna l  t ransduct ion  events such  as  t he  tyros ine  k i nase 
pathway. 1 42 
Recent ly ,  May and co-workers demonstrated t hat bryostat i n  1 ,  a novel 
non-tumor promoting PK-C activator, supported the in vitro growth of mu lt ipotent 
h u man h ematopo iet ic  progen ito rs , 1 23 although addi t iona l  studies by t hese 
i nvest i gators suggested t h at i nd i rect,  accessory ce l l  med iated effects 
contributed to th is  phenomenon . 1 24, 1 25 Subsequently, our g roup reported that 
bryostat i n  1 and phorbol 1 2 , 1 3-d i buty rate (PDBu)  s ig n i ficant ly i ncreased the 
formation  of comm itted myeloid progen ito rs (day 1 4  CFU-GM) by human bone 
marrow mononuclear cel ls i n  response to recombi nant GM-CSF (rG M-CSF) . 1 26 
Together, these f ind ings suggest an i mportant ro le fo r PK-C act ivat ion i n  the 
regu lat i on  of human hematopo i es is ,  possib ly  at  t he  leve l  of  g rowth factor  
re lease and/or progen itor ce l l  responsiveness toward HGFs. 
Hypothesis and Objectives 
To date most molecu lar and biochem ical i nformat ion  concern ing s ignal  
t ransduct ion of H G Fs derives from hu man or  muri ne ce l l  l i nes which exh ibit 
defects in ce l lu lar genetic prog rams responsib le for the coup l ing of p ro l iferat ion 
with different iat ion  or  l i neage commitment i n  response to t hese compounds .  
Lim i ted avai lab i l ity of normal bone marrow stem/progen itor ce l ls  has made i t  
d iff icult to corre late mo lecu lar and bioche mical analysis of  s ignal  t ransduct ion 
processes with normal  ce l l u lar g rowth  and l i neage com m itment  i nduced by 
HGFs.  I nformation  concern i ng the mechanism by which the  sig nals i nduced by 
H G Fs control  no rmal hematopoiet ic cel l  g rowth and l i neage com m itment is 
cu rrently lacki ng .  The in format ion from prev ious stud ies o n  hematopoietic ce l l  
l i nes suggests PK-C activ ity i s  i nvolved i n  GM-CSF and IL-3 signal  transduct ion .  
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We therefore hypothesized that pharmacological manipu lat ion of PK-C activity 
might  exert specific effects on the g rowth and l i neage commitment of p rimary 
cu ltu res of h u man  hematopoietic prog e n i to r  ce l ls  exposed to these two 
cytoki nes, and perhaps other HGFs .  
Si nce transformed ce l l  l i nes usual ly do  not  differentiate i n  response to 
HGFs ,  it is i mportant to employ normal hematopoi etic cel ls as a model  to 
examine  events i nvo lved i n  l i neage comm itment and d i ffe rent iation  of normal 
hematopoietic progen itor cel ls .  Our hypothetical model h o lds that s i nce HGFs 
can i nduce rapid alterati o n  of the phosphory lati on  status o f  key s igna l 
transducing prote i ns  v ia tyrosi ne ki nase and PK-C pathways, manipu lation  of 
t h e s e  key s i g n a l  t ra n s d u c i n g  k i nases ,  part i cu la r l y ,  P K - C ,  t h ro u g h 
p harmaco log ical  means shou ld exert specif ic effects o n  the g rowth and 
d i fferentiation  of  normal human bone marrow progen itor ce l ls exposed to  HGFs .  
Th is  project was aimed at 1 )  determ in i ng whether PK-C activators can modulate 
the formati o n  of C FU-GM (an assay for comm ited macrophage ,  neutroph i l ,  
eosi noph i l  progen itors ) ,  BFU-E (an  assay for  early e ryth ro id proge n itor cel ls) , 
and CFU-GEMM (an assay for early multipotent progen i to r  cel ls)  co lon ies by 
e nr iched bone marrow progen itor ce l l  popu lations exposed to GM-CSF, IL-3, 
p 1 XY32 1 , and SCF;  2)  document i ng whether  PK-C activators act d i rectly o n  
prog e n i to r  ce l l s  o r  i n d i rectly o n  bone marrow accessory (stro mal )  ce l ls to 
modulate those processes ; 3) compari ng tumor  promoti ng (e .g . ,  phorbol esters, 
mezerei n )  and non-tumor promoti ng (e . g . ,  byostati n 1 )  PK-C activators in thei r 
modu lati ng effect o n  normal hematopoies is ;  4) accumu lating  i nformation  o n  the 
schedu l ing and k inetic aspects of these agents as pharmaco log ic  probes i n  
s ignal  transduction  studies. 
M AT E R I ALS A N D  M ETHODS 
R e agen ts Al l  t i ssue cu ltu re reagents were obtai ned from G IBCO (Grand 
Is land, NY) un less otherwise stated. Bryostat in  1 was extracted and purif ied from 
Bugu/a neritina as previously descri bed. 1 17 Phorbol 1 2 , 1 3-dibutyrate (PDBu) ,  
mezere i n  and non -PK-C st i m u lat i ng phorbo l  ester, 1 43 4 a-P h o rbo l  1 2 , 1 3-
D idecanoate (4 a-PDD)  were obtai ned fro m  L .C .  Serv ices (Wobu rn ,  MA) .  
Bryostat in  1 ,  PDBu ,  mezere in  and 4 a-PDD were dissolved i n  DMSO at 1 0-4 M 
and d i luted i n  complete med ium just prior to use. D MSO has been tested and 
shown to exert no  effect on colony g rowth and d ifferent iat i on  at veh ic le  
concentrations .  Recombi nant hu man I L-3 ( r IL-3)  and CSF-1  (rCSF- 1 ) were 
p rov ided by D r .  Jay Sto ude m i re ,  (Genet ics I n st i tu te ,  Cambridge ,  MA) . 
Recom binant human GM-CSF was a g i ft from Dr. Paul Trotta, (Scheri ng Corp . ,  
B loomf ie ld ,  NJ ) .  Recomb i nant hu man I L-5 ( r I L-5) and  G-CSF ( rG-CSF) were 
purchased from Amgen (Thousand Oaks, CA) .  G M-CSF/ IL-3 fusio n  prote in  
(p IXY32 1 ) was generously provided by Immu nex (Seatt le ,  Wash ington ) .  H uman 
recombi nant e rythropoiet i n  ( rEpo) is obtai ned from Connaug ht Laboratories ,  
LTD (Wi l lowdale, Ontario ) .  Human recombi nant stem cel l  factor ( rSCF) i s  a 
ki ndly g i ft by D r. Thomas Huff (Department of Microbiology and Immunology, 
Medical Co l lege of Virg ia ,  Vi rg i n ia  Commonwealth U n i versity ) .  Cond i t ioned 
medium from the cel l  l i ne 5637 was harvested f rom conf luent cultures, f i ltered 
and stored at -200 C . 1 44 Rabbit ant i - human  CSF- 1 and G-CSF po lyclona l  
antibodies were purchased from Genzyme (Boston ,  MA) .  
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Bone Marrow CD34+ Cell Separation The CD34 antigen is currently 
unique in its narrow specificity of expression on human Iymphohematopoietic 
progenitor cells (Fig. 6). Preliminary results of transplantation studies in primates 
and humans indicate that the stem cell capable of reconstituting 
/ Pluripotent Stem 
(CFU-GEMM) � • 
Multipotent Myeloid Progenitor Lymphoid Progenitor 
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Lymphocyte 
Figure 6. Hematopoietic Hierarchy and CD34 Expression. 
Darkness of shading indicates intensity of cell surface CD34 
expression. 
1 
Iymphohematopoiesis in myeloablated recipients is CD34 positive. In vitro 
colony forming unit assays (CFU assay) suggest that CD34 expression (presents 
on only 1.5% of low-density Ficoll-Hypaque separated marrow mononuclear 
cells) exists essentially in all multipotent and most bipotent and unipotent 
myeloid progenitor cell populations in bone marrow cells.145 The development 
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of the  immunomag netic pu rif icat ion  techn ique and general avai labi l i ty of the  
anti-CD34 monoclonal ant ibody make CD34+ selection  a rout ine  procedure for 
e n ri ch i ng  h e matopo iet ic  stem/pro g e n i to r  ce l ls  ( F i g .  7 ) .  Th i s  p rocedu re 
substantial ly e l im i nates accessory cel l  populat ions in bone marrow samples so 
that the confounding effects of secondary growth factors re leased in cu ltu re are 
m i n im ized . Another  advantage of us ing en riched progen itor cel l  populations i s  
the i mproved clo n i ng effeciency for  bone marrow cu ltu res .  By us ing th i s  ce l l  
populat i on ,  conside rably lower ce l l  densit ies can  be plated (e . g . ,  1 000-4000 
CD34+ cel ls/ml vs.  50 ,000-1 00,000 nonadherent ,  T ce l l  depleted bone marrow 
cel ls/m l )  to ach ieve an equivale nt colony g rowth ,  and th is  also g reat ly reduces 
the  possibi l ity of ce l l -cel l  contact, wh ich may also confound i nterpretat ion of the 
effect of  g rowth factors or pharmacologic agents tested i n  the culture .  
I n  the  present experi ments bone marrow aspi rates were obtai ned with 
i nformed consent from the poste ri o r  i l iac crests of healthy volu nteers.  These 
stud ies have been approved by the Human I nvest igat ions  Committee of the  
Medical Col lege of Vi rg i n ia .  The ce l ls were passed throug h  26 gauge needle to  
d isperse c lumps and di luted 1 :5 i n  McCoy's 5a med ium contai n i ng preservative 
free hepari n .  The mononuc lear cell fract ion  was recovered f ro m  a Fico l l ­
Hypaque g rad ient ,  washed th ree t imes, resuspended i n  fresh med ium wi th  1 0% 
fetal bov i ne  serum (FBS)  (HyClone Laborator ies,  I nc. , Logan,  Utah ) .  After  
i ncubat ion i n  culture flasks a t  37°C i n  a i r  with 5% C02 for  e i ther 90 m i nutes or  
overn i ght ,  t he  non-adhere nt mononuclear ce l l  populat ion was then recovered 
and i ncubated w i th  an t i -CD34 m o n oc lona l  ant i body ( Becton  Dick i nson  
Immunocytometry Systems, Mountai n View, CA) at 4°C for 60  minutes. The  cel ls 
were subsequent ly washed twice in med ium with .2% bovi ne  seru m  album in  
and  i ncubated with goat ant i -mouse I gG coated M-450 immunomagnetic beads 
(Dynal I nc. , G reat Neck, New York) employing a bead : total ce l l  rat io  of 1 : 35. 
The bead/cel l  mixtu re was gently vortexed and centrifuged at 400 g for 1 0  m in  
BM aspi rates 
ce ntrifu ge 
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F igure 7.  Separat ion of Bone Marrow CD34+ Cel ls 
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to obtai n opti mal rosette format ion .  The ce l ls  were further  i ncubated at 4°C with 
gentle ag itat ion for 30 m i nutes. Rosette format ion was inspected in a phase­
contrast m icroscope and rosettes and free part icles were mag netical ly removed. 
The C D34 + cel l  fract ion was washed twice and resuspended at the appropriate 
ce l l  density for plating .  
Colony Formi ng Assays Semiso l id  cu ltures were employed i n  a l l  of the 
co lony form ing assays (F ig .  8). I n  th is  cu l ture cel ls are even ly d istributed and 
p lated i n  e i ther an agar or  methy lcellulose medium mixtu re i n  smal l  wel ls  with 
one ml cu lture vo lume.  This techn ique a l lows 1 )  assessment of ce l l  prol ife ration  
and l i neage comm imtment from a s ing le  proge nitor ce l l ;  2)  exam inat ion of the 
s ing le H G F  effects, e i ther  a lone  or in  comb i nat i on  wi th o ther  H GFs and 
p harmacolog ical agents ; 3) characterizat ion of heterogeneous colony subsets ; 
and 4 )  de l ineation  of d iffus ib le i nte ract ions between plated ce l ls . 1 46 The H G Fs 
i n  the culture and the length of cultu re period dete rmine the type of progen ito rs 
exami ned.  
I. CFU-GM assay I n  part i cu la r ,  C F U - G M  ( c o l o n y  fo rm i ng u n i t -
g ranu locyte,  macrophage/monocyte) assay exam i nes t h e  g rowt h  and l i neage 
com m itment of u n i potent or  b i pote nt myelo id macrophage and g ranu locyte 
proge nitor ce l ls in a period of 1 4  days. These ce l ls are usual ly i n  the late stage 
of hematopoietic he i rarchy. The cell types i n  the co lonies derived from th is  assay 
are p u re macrophage ,  pu re gran u locyte or macrophage  and g ranu locyte 
m ixture .  SCF,  I L-3, GM-CSF, G-CSF and CSF-1  have been general ly used as 
growth factors for th is  assay . 1 46 
I I. C FU-G EMM and BF U-E assays U n d e r  t h e  s a m e  c u l t u re 
condit ions u sed for CFU-GM,  CFU-GEMM (co lony form i ng un it-g ranu locyte ,  
g rowth factors and other agents 
hematopoietic progen itor ce l ls  
sem iso l id 
med i u m  
3 7  ·e , 5% 0 2 and 5% C02 
day 14 co lon ies 
Figu re 8 .  Colony Forming Assay 
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e ryth rocyte,  macrophage ,  megakaryocyte)  and BFU-E  (burst form i ng u n it­
e ryth rocyte)  are performed in the presence of rEpo, a d i ffere ntiation  factor for 
e ryth ro id co lon ies ,  in conjunct ion  with other early stage mye loid proge n itor  
g rowth factors, such as IL-3, GM-CSF or SCF. Such combinat ions support both 
e ryt h rOid and e rythro id/mye loid mi xed colony as we l l  as CFU-G M g rowt h .  The 
colon ies  contai n i ng  both e rythroid and myelo id l i neages are considered to be 
derived from ear ly mu lt i potent progenitor cel ls .  These two assays wi l l  determ i ne  
the g ro wth and different iati on o f  mu lt i  potent early hematopoietic progen itor cel ls 
(CFU-G EMM)  as wel l  as early com m itted e rythroid progen itor cel ls ( BFU­
E ) . 1 47, 1 48 
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I I I .  Cel l  Cu l ture Condi t ions I n  the present stud ies C D34+ bone marrow 
cel ls contai n ing CFU-GM, BFU-E and CFU-GEMM progen itor  cel ls were cloned 
i n  soft agar as previously described. 1 26 Briefly, ce l ls were plated i n  a double 
layer soft agar system i n  22 mm 1 2  wel l  p lates (Corning Laboratory Sciences 
Company ,  Corn i n g ,  NY) .  The bottom layer consisted of 0.5 ml McCoy's 5a 
med ium supplemented with sod ium pyruvate, essential and non-essential amino 
acids , MEM v i ta m i ns ,  seri ne ,  asparag i ne ,  g lutam ine ,  pe n ici l l i n ,  streptomyci n ,  
0 .5% bacto agar (D ifco , Detroit, M I )  and 20% FBS. The top  layer contai ned 4000 
(2000 in experi ment with SCF) CD34+ ce l ls in 0 .5  ml supplemented McCoy's 5a 
medium with 20% FBS, and 0 .3% agar. After the agar is al lowed to ge l ,  0 . 1  m l  
of m ed i u m  contai n i ng  exper imental agents i s  added to each we l l .  We have 
previously demonst rated that when factors are added in th i s  manner, colony 
formation  is equivalent to that obtai ned when factors are i nco rporated i nto the 
bottom layer o r  i ncorporated i nto both the top and bottom layers. 1 26 The plates 
are then placed in a 3JOC, 5% 02 , 5% C02, fu l ly humid i fied i ncubator. After 1 4  
days, fresh co lon ies were scored u t i l i z i ng an i nverted microscope and then  
cytochemical ly stai ned for  myeloid l i neage marke r (see next sect ion for detai l ) .  
I n  some CFU-GEMM and BFU-E assays performed with p 1XY32 1 , rEpo, 
and bryostat in  1 ,  CD34 + bone marrow ce l ls were cu ltu red at a density of 4 x 1 03 
Im l/35 m m  Petri d ish  i n  I scove's Mod if ied Du lbecco's Med iu m ( IMDM)  further  
supp leme nted with sodi u m  bicarbonate,  ant ib iot ics ,  L-g lutam ine ,  2 -ME (2-
m e rcaptoethano l )  (5 x 1 0-5M) ,  Sod ium selen ite (5. 6 x 1 0-8 M) ,  bov ine  seru m 
album in  (0.3%),  H uman se rum ( 1 0%) , fetal bov ine  serum (30%), Methylce l lu lose 
(2%) ( S igma, St . Lou is ,  MO) and rEpo ( 1  u n it/m l ) .  The Petri d ishes were then 
placed in  a 37oC,  5% 02, 5% C02,  fu l ly  hum idi f ied i ncubator. After 1 4  days, 
BFU-E and CFU-GEMM colonies were scored as ment ioned next .  
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IV. Colony Scor ing  Cr iteria For CFU·GM assay co lonies consisting o f  5 0  o r  
more cel ls  with g ranu locytic or macrophage- l i ke appearance were scored as 
CFU-GM. For BFU-E assay colon ies consisting of more than o ne g lobu lar g roup 
with 1 5  o r  more hemoglob in ized cel ls i n  each g roup were identified as BFU-E,  
wh i le colon ies consisti ng of m ixed hemoglobin ized and wh i te blood (> 50) ce l ls 
were counted as CFU-GEMM uti l iz ing an i nverted microscope. 
Colony Ch a racte r izat i on  Cel lu lar esterases represent a series of  d isti nct 
e nzymes act ing upon select substrates.  Under defi ned reaction condit ions, it i s  
possible to  determine hematopoietic ce l l  types, especia l ly those immature ce l ls 
of neutroph i l  and macrophage/monocyte l i neages i n  the i r  late developmental 
stage s . 1 49 To perform the test, fixed colony ce l ls  are i ncubated with either 
naphtho l AS-D ch loroacetate or  a- naphthyl acetate in the presence of fresh ly 
formed d iazon i um salt. Enzymatic hyd ro lysis of este r l i nkages l i be rates free 
naphtho l  compounds.  These couple with the d iazo n i u m  salt, form i ng h igh ly 
colored deposits at sites of enzyme activity .  Luxol Fast Blue is found specifical ly 
to sta in for eosi nophi l  g ranu le . 1 50. 1 5 1 It is thought that a specific basic protein  in 
the g ranu le i s  responsib le for this reactio n . 1 50 In present studies colony types 
were characte rized uti l iz ing a prev iously described in situ tri ple stai n techn ique 
combin ing esterase stai n i ng with Luxol  Fast B lue . 1 52 Briefly, ce l ls were f ixed by 
add ing  1 m l  of citrate-acetone- methano l  (CAM) fi xative to the wel ls  for  1 0  
minutes, wh ich were then washed th ree t imes with d isti l led water. The ce l ls were 
then stained for the presence of a-naphthyl acetate este rase (monocytic l i neage 
maker) and naphthol AS-D chloroacetate esterase (neutroph i l ic l i neage marker) 
uti l i z i ng  com merc ia l ly avai lab le k its (S igma ,  St.  Lou i s ,  MO) .  Fo l low ing  
cytochemical sta in ing the  plates were submerged i n  water, and the  agar disks 
f loated to the surface and transfered to g lass sl ides. After dry ing ,  the sl ides were 
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stained with 0 . 1  % Luxol Fast Blue solut ion (for eosi nophi l ic l i neage) (0 . 1  g Luxol  
Fast B lue i n  1 00 m l  of 70% ethanol satu rated with u rea) for 60 minutes at room 
t e m p e ratu re .  The t r i p l e  sta i ned s l ides were then  counter-stai ned w i th  
H ematoxyl i n  Solut ion G i l l  NO . 3.  The specificity of these stai n i ng techniques was 
d e m o n st rated by t he  observat i on  t hat an t i -CSF- 1  neut ra l i z i ng  ant ibody 
selectively blocked CSF- 1 , a macrophage colony g rowth factor, i nduced g rowth  
of those co lon ies  stai ned by  a-naphthy l  acetate esterase react ion  (ANAE 
positve) whereas anti -G-CSF se lect ively b locked G-CSF, a neutraph i l  g rowth 
facto r, i nduced co lon ies stai ned by naphthol  AS-D ch lo roacetate este rase 
react ion .  The eryth ro id colon ies were stai ned by Hematoxy l i n  and cou ld be 
easily dist i nguished from other l i neages. Th is  procedure offers the advantage of 
preserv i ng  a l l  t he  co lon ies  i n  o ri g i na l  spat ia l  o rie ntat ion  as we l l  as the i r  
morpho logy ; furthermore,  t he  sl ides can be  kept for years without fad ing .  
Schedul i ng Coord inat ion  S t u d i e s  F o l l o w i n g  i n i t i a l  act i v at i o n ,  
sustained exposure to PK-C activators such as PDBu o r  b ryostati n 1 leads to 
i nactivat ion  and deg radat i on  of PK-C enzyme .  Th is  dual  act i on  of PK-C 
activators i s  we l l  docu mented i n  studies i nvo lv ing many cel l  types i nc lud ing 
h e matopo iet i c  ce l l s . 1 53 S i nce CFU assay i nvo lves long term cultu re ,  i t  is  
i mportant to obtai n the i n format ion i nvolv i ng these processes .  To defi ne the 
s i gna l  coordi nat ion betwee n PK-C mani pu lat i on  and r I L-3 ,  the effects of  
schedu l ing on  hematopoiet ic ce l l  growth were assessed by exposing cel ls  i n  the 
agar cu lture p late to bryostat in  1 for i ntervals rang ing from 0- 1 44 hours prio r  to, 
or fo l low ing , adm i n i strat ion  of r IL-3. CFU-GM co lony g rowth and l i neage 
com posit ions  u nder such cond i t ions were characterized and compared with 
those obtai ned by s imu ltaneous admin istratio n of  both agents at the i n it iat ion of 
culture. 
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L imiting D i lution Studies Bryostat i n  1 and PDBu have been shown to 
i nduce secondary re lease of several types of HGFs i ncluding G M-CSF, I L-3, G­
CSF and C S F- 1 by bone marrow accessory ce l ls . 1 2 5 . 1 3 5 Despite the 
i m m u n o mag net ic pu rif icat ion  of  CD34+ ce l ls ,  the possi bi l i ty that  res idual  
accessory cel ls  may i nflue nce colony formation  can not be completely excluded. 
To determ ine  what effect, i f  any, PK-C act ivators have on CD34+ myeloid 
progen itor cel ls ,  l i miti ng d i lution stud ies were performed to establ ish whether the 
effects of  these agents cou ld be d i luted out at low ce l l  density culture .  Brief ly,  
C D34+ cel ls were p lated i n  agar cu lure wel ls with the density of 4000 , 2000, 
1 000, 500 ,  250, 1 25 ,  and 62 cel ls/ 1 m l  wel l .  Each ce l l  density was performed i n  
quadrupl icate . The day 1 4  CFU-GM colon ies were scored and cytochemical ly 
characterized as described previously .  
Neutra l iz i ng Ant ibody Stud ies For reasons stated above, i n  o rder to 
neutral ize possib le secondary factors re leased by residual  accessory cel ls ,  
i nc lud ing G-CSF and CSF- 1 , ant i -G-CSF and anti -CSF-1  polyclonal  rabbit 
antibodies were e mployed to absorb these putative H G Fs .  Brief ly, ant i -G-CSF 
and anti -CSF- 1 , e i ther alone or in combi nat ion ,  were i ncorporated i nto the top 
layer of the agar medium .  The opti mal concentrations for neutra l iz ing anti bodies 
were determined by se lective i n h ib i t ion of more than 50% of n eutroph i l  colony 
formatio n  i nduced by rG-CSF i n  conjunct ion  wi th p l XY32 1 (for ant i -G-CSF 
anti body) ;  o r  macrophage colony format ion i nduced by rCSF-1  i n  conjunction 
wi th  p l XY32 1 (fo r ant i -CSF- 1 ) . The speci f i c i ty of i n h i b i ti o n  has been 
demonstrated by  the  f i nd ing  t hat i n  the  presence of  p lXY32 1 , ant i -G-CSF on ly 
b locks rG-CSF i nduced neutroph i l  deve lopme nt, and exerted no  effect o n  
macrophage g rowth  i nduced b y  rCSF-1 , and vice versa. These two antibodies 
have no  i nh i bito ry effects on  eosi noph i l  co lony g rowth sti mu lated by p lXY32 1 , 
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alt hough  ant i -CSF- 1 did b lock macrophage co lony format i on  i nduced by 
plXY32 1 as shown in the results section .  
Statistica l A na lysi s  Data are presented a s  mean±SE o r  mean±SD as 
described i n  tables and f igures .  To compare the mean values from smal l  
samples, a Student's pai red or non-pai red t test was used and differences were 
considered s ign ificant when P < . 05 .  
R E S U LT S  
1 .  Effects o f  PK-C a ct ivat i n g  agents on rG M-CSF o r  r 1L-3 i nduced 
colony formation by CD34+ cells To determine the effects of various PK-C 
activators on  t he growth and l i neage commitment of iso lated CD34+ myeloid 
proge nitor cel ls,  PDBu,  mezere i n ,  and bryostat i n  1 were adm in i stered either 
alone or i n  combinat ion with rG M-CSF or r1 L-3 in day 1 4  CFU-GM assay .  The 
effect of vary ing concentrati ons of bryostat i n  1 ,  PDBu ,  and mezerei n on rG M­
CSF and r1 L-3 i nduced colony format ion  i s  i l l ust rated by the data i n  F igure 9 .  
None  o f  the PK-C activators supported colony format ion  when  admin iste red 
alone .  However, when 1 - 1 00 nM bryostat in  1 was combined with concentrat ions 
of rGM-CSF or  r 1 L-3 that had been dete rmined to yield maximal co lony numbers 
when adm i n istered alone  (e . g . ,  50 ng/m l ) ,  co lony format ion i ncreased by more 
than 1 00% i n  each case (p < . 0 1 ) .  The mean number  of co lonies formed i n  the 
combi ned presence of rG M-CSF or r 1L-3 and 1 0  nM bryostatin 1 (e .g . ,  1 52±28, 
mean±SE,  n=7, and 1 1 6±1 6 ,  n=1 3 respectively) was equivalent to that observed 
i n  t he  presence of 1 0% 5637 condi t io ned med i u m  ( 1 35±8, n=26) o r  t he  
combinat ion o f  r 1L-3 and rG M-CSF ( 1 1 2±1 5,  n=5). 
In contrast, h igher concentrat ions of PDBu (e .g .  50 nM) reduced r 1L-3 and 
rG M-CSF co lony format ion (F igu re 9 ) ,  and e l im i nated g rowth en t i re ly  at 
concentrat ions > 1 00 n M  (data not shown) .  However, lower concentrat ions of 
PDBu (e .g . ,  25 nM)  i ncreased co lony format ion (p < . 0 1 ) in response to either 
r 1L-3 ( 1 1 4±23, n=6)  or  rG M-CSF ( 1  04±25, n=5) to levels equ ivalent to those 
obtai ned with 1 0% 5637 conditi oned med ium ( 1 35±8, n=26) or  with bryostati n 1 . 
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Conce ntrat ion of PK-C St i m u la t i n g  Agent ( n M) 
Figu re 9. The effect of vary ing concentrat ions of PK-C activat ing agents 
on day 1 4  CFU-G M.  CD34+ cel ls  were exposed to PK-C act ivators in 
conjunct ion with 50 ng/ml rGM-CSF or 50 ng/ml rIL-3, and the number  of 
day 1 4  CFU-GM determined. Values represent the mean ± SE for 
mu lt ip le i ndependent experi ments (n=3 to 20) performed in tri pl icate .  The 
number of co lon ies obtai ned with 1 0% 5637 condit ioned med ium is 
provided for comparison .  No co lon ies were observed when PK-C 
sti mu lat ing age nts were admi n istered a lone.  
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S i m i lar  resu lts were obtai ned with the PK-C act ivat i ng agent ,  mezere i n ,  
although optimal stimu latory as well as i nh ibitory concentrat ions were lower than 
those observed in the case of PDBu.  
I n  v iew of the abi l ity of bryostat in  1 to block those phorbol ester mediated 
effects that i t  does not share, 1 1 8 , 1 1 9 , 1 54 separate stud ies were performed to 
dete rmine whether bryostat i n  1 could reverse the i n h i bi tory effects of h igh  
conce nt rations of  PDBu  or meze re in .  Coadmin istrat ion o f  50  nM P D Bu with 50  
ng/ml of either rGM-CSF or  r 1L-3 resu lted i n  a 90% reduct ion i n  co lony format ion ,  
H owever, when 1 00 nM bryostat i n  1 was added to the  combi nat i on ,  the 
i nh i bitory effects of PDBu were abrogated and co lony formation  was equivalent 
to that i nduced by the g rowth factor and bryostat i n  1 .  For example ,  i n  a 
representative experi ment (Table 1 . ) ,  the combinat ion of 50 nM PDBu and rGM­
CSF or r1 L-3 gave ri se to 8±6 (vs. 75±1 1 ,  P < .00 1 ) and 7±4 (vs. 68±1 4, p < . 0 1 ) 
colon ies respectively ; these va lues i ncreased to 1 56±27 (p < ,001 ) and 1 22±29 
(p < . 0 1 )  when bryostat i n  1 was present .  S im i lar resu lts were obtai ned with 
mezerei n .  However, 1 00 nM bryostat i n  1 was not able to reverse the i n h ibi t ion 
of colony format ion observed when ce l ls were pre incubated 24 hours with 50 nM 
PDBu and r 1L-3 (data not shown) .  
These resu lts demonstrate that a l l  t h ree classes of PK-C act ivators 
enhanced colony format ion  by CD34+ bone marrow ce l ls  exposed to r1 L-3 or  
rG M-CSF,  alt hough  the opt i mal  st i mu latory dose var ied wi th each agent .  
Furthermore ,  the i nh ib i tory effects of PDBu and  mezere i n  at h igher  dose leve l 
were blocked by bryostat in  1 .  Th is f ind ing i s  consistent with the results from other 
cel l  systems. 1 1 8 , 1 1 9 , 1 54 and also i ndicates that there i s  a d i fference between 
t u mo r  pro moti ng  and n o n -pro mot ing PK-C activators wi th respect to t he  
mechan isms mediat ing thei r effects. 
Table 1 .  Bryostat in  1 Reverses the Inh ibitory Effect of PDBu 
Med ium PDBu  bryostat in  1 
bryostat in 1 
+ PDBu 
rGM-CSF 75±1 1 8±6 * 1 57±22 t 1 56±27 t 
r1L-3 68±1 4 7±4 * 1 29±5 t 1 22±29 t 
Values represent mean ± SD (tri pl icate) of day 1 4  CFU-GM/4000 CD34+ 
cel ls for one representative experi ment .  Two addit ional experi ments 
y ie lded s im i lar resu lts. Student's t-test was appl ied for the compari sons 
between g roups. Concentrat ion of tested agents : r IL-3, 50ng/m l ;  
rGM-CSF, 50ng/m l ,  PDBu,  50n M ;  bryostat in  1 1 00 nM.  
* s ign i ficantly less than values for the growth factor alone (p < .00 1 ) .  
t s ign i ficantly g reater than values for the growth factor alone (p < .01 ) .  
t sign i ficantly g reater than values for  the  combi nat ion o f  PDBu and growth factor alone (p < .0 1 ) .  
3 7  
2 .  Effect of PK-C act i vators on  the l i neage commitment of  day 1 4  
C FU-GM st i m u lated by rG M-CSF and/or r 1 L-3 To dete rm i ne whet h e r  
PK-C activators alter  t h e  response o f  committed myeloid progenitors t o  r 1L-3 and 
rGM-CSF in a l i neage-speci fic manner, characterizat ion of day 1 4  co lon ies was 
carried out employ ing cytochem ical techn iques (Table 2 ) .  When ce l ls were 
cultu red i n  the presence of 50 ng/ml rGM-CSF alone,  43% of the colonies were 
p u re ly eos i noph i l i c  i n  nat u re and a total of 52% co ntai ned eos i noph i l i c  
components.  When cel ls were cul tured i n  the combined presence o f  1 00 nM 
b ryostat i n  1 and 50  ng/m l rG M-CSF, a two-fold i ncrease was observed i n  the 
total number of co lonies, (compared to rG M-CSF alone) but the absolute number 
of eosi noph i l ic  colon ies remai ned constant (e . g . ,  2 1 ±3 vs.  20±2) . S ig n ificant 
i ncreases were noted in the number of pu re macrophage (e .g . ,  29±6 vs. 1 1 ±2) ,  
Table 2 .  Effect of PK-C Activators on  the Growth and Lineage Commitment of Myeloid 
Progenitors E xposed to rGM-CSF and/or r1 L-3 
Day 1 4  C FU-GM/ 4000 CD3� cells plated 
Stimuli 
Eos/M N/M Total n Eos M N 
rGM-CSF 20 ± 2 ( 4 3 )  4 ± 1 (9)  1 1  ± 2(24) • 3 ± 1 ( 7 )  • 8 ± 3 ( 1 7 ) . 46 ± 7 1 2  
rGM-CSF + Bryo 1 2 1  ± 3 ( 2 1 ) 8 ± 1 (8)  
rGM-CSF + PDBu 7 ± 3 ( 7 ) :1: 2 ± 1 (2) 
rGM-CSF + Mezerein 1 2  ± 3 ( 1 4 ) :1: 2 ± 1 (2) 
29 ± 6(29) . 1 1  ± 4( 1 1  ) 
48 ± 1 8 (50) • 1 4  ± 6( 1 5) 
36 ± 1 3 ( 4 1 ) 1 7  ± 6(20) 
31 ± 9 (3 1 ) 
25 ± 9(26) 
20 ± 8(23)  
99 ± 16 • 7 
94 ± 1 6  
• 
4 
86 ± 1 6  • 5 
r1L-3 27 ± 4 ( 6 0 )  5 ± 1 ( 1 1 )  7 ± 1 ( 1 6 ) • 2 ± 2(4) • 4 ± 1 ( 9 )  • 46 ± 6 1 3  r 1L-3 + Bryo 1 1 2  ± 2 ( 1 1 ) :1: 4 ± 1 ( 4 )  4 2  ± 1 3 (38)  
• 1 8  ± 4 ( 1 6 )  3 6  ± 6(33) • 1 1 0  ± 1 3  
r1L-3 + PDBu 7 ± 3 ( 9 ) :1: 2 ± 1 (3)  4 4  ± 1 3 (55)  • 7 ± 3(9) . 
20 ± 1 1  (25) • 80 ± 1 8  
• 
r1L-3 + Mezerein 3 ± 1 (2) :1: 0 ( 0 )  6 9  ± 3 7 ( 4 8 )  1 7  ± 7( 1 2 ) 55 ± 9(38) 1 45 ± 27 • 
rGM-CSF + r1L-3 5 4  ± 3 ( 4 8 )
' 1 6  ± 2 ( 1 4 )  
• 
1 2  ± 3 ( 1 1 )  1 2  ± 5 ( 1 1 )  1 8  ± 5 ( 1 6) 
• 
1 1 2 ± 1 5  
rGM-CSF + r1L-3 + Bryo 1 9 ± 3 ( 7 ) :1: 6 ± 2 ( 5 )  :I: 60 ± 2 1  ( 4 5 )  1 0  ± 4 ( 8 )  4 9  ± 1 1  ( 3 7 )  1 32 ± 1 3  
Cel ls were plated i n  the presence of rGM-CSF (50ng/ml )  and/or r1L-3 (50ng/ml)  i n  conjunction with 
either bryostat in 1 ( 1 00nM) ,  PD Bu (25nM),  or mezere in  ( 1 2 .5  nM).  Values represent the means ± SE 
for n separate experiments. The Student's t-test was applied for comparisons between samples. 
Figu res i n  parentheses co rrespond to the percentage of each colony sub-type relative to the total 
number of colon ies .  Abbrev iat ions :  Eos,eosi nophi l ;  M, monocyte/macrophage ;  N, neutrophi l .  
• significantly greater than val ues for growth factor(s) alone (p < 0.05). 
:t: significantly less than values for g rowth factor(s) alone (p < 0.05). 
6 
4 
4 
5 
6 
w 
00 
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(e .g . ,  31 ±9 vs. 8±3) co lon ies (p < .05 i n  each case) .  Consequently, the i ncrease 
in g rowth of these non-eosi nophi l ic  colony subtypes was responsib le for  the 
potentiat ion of total cOlony format ion i nduced by b ryostatin 1 i n  conjunct ion with 
rGM-CSF. 
The response of ce l ls to rGM-CSF and ei ther 1 2 .5 nM mezere in  or  25 nM 
PDBu was s imi lar to that of cel ls exposed to rGM-CSF and 1 00 nM b ryostatin 1 ,  
i n  that s ig n i ficant i ncreases were noted i n  both the  abso lute n umber  and 
pe rcentage of macrophage,  neut roph i l ,  and m i xed neutroph i l -macrophage 
co lon ies,  compared to ce l ls exposed to rGM-CSF alone.  However, in contrast to 
combinat ions contai n ing b ryostat in 1 ,  wh ich were associated with a reduction i n  
t h e  percentage b u t  not t h e  absolute numbe r  of  eosi noph i l ic  co lon ies ,  co­
admin ist ration of P D Bu or mezere in  with rG M-CSF s ign i f icantly reduced the 
absolute number of pure eosi nophi l ic co lon ies (e .g . ,  f rom 20±2 to 7±3 and 1 2±3 
respectively;  p < .05) .  
When cel ls were exposed to 1 00 nM b ryostati n 1 i n  conjunct ion with 50 
ng/ml  r 1L-3 (Table 2) ,  the i ncrease i n  the total number of co lonies was si mi lar to 
that observed when bryostatin 1 was combined with rGM-CSF. In add ition ,  co­
adm i n ist rat ion of  bryostat i n 1 with r 1L-3 s ign if icantly enhanced the absolute 
number (and pe rcentage) of pure macrophage (42±1 3 vs.  7±1 ) ,  pure neutroph i l  
( 1 8±4 vs.  2±2) ,  and mi xed neutroph i l -macrophage (36±6 vs.  4±1 ) co lon ies (p < 
. 05  i n  each case) .  Col lect ive ly .  these i ncreases were respons ib le for  the 
potentiation of total colony formation when bryostati n  1 was combined with rI L-3.  
H owever ,  in contrast to the resu lt s  of stud i e s  em p loy i ng  rG M-CSF.  
coadmin istrat ion o f  bryostat in 1 with r 1 L-3 produced a s ignif icant decrease i n  the 
abso lute nu mber ( in add i t ion to the re lat ive percentage) of pure eosi noph i l ic  
colonies compared to r 1 L-3 a lone (e .g . ,  1 2±2 vs.  27±4;  p < .05) . F ina l ly ,  co­
adm i n ist rat ion of r 1L-3 with e i ther 25 nM PDBu or  1 2 . 5  nM mezere in  yie lded 
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resu lts t hat were ident ica l  to t hose obse rved with 1 00 n M b ryostati n 1 .  
Specifical ly, sign i ficant i ncreases i n  the number of pure and m i xed neutroph i l­
macrophage  colonies were noted, whi le both the absolute number and relative 
percentage of eosi noph i l ic colon ies substantial ly decl i ned with the addit ion of 
PDBu or mezere in  (p < .05 in each i nstance) .  
The  effect o f  b ryostat in  1 on  t he  l i neage specificity of colon ies derived 
f ro m  CD34+ cel ls cu ltu red in the presence of both r 1 L-3  and rG M-CSF is 
i l l ustrated by the data shown in Table 2 .  As previously reported 1 55, exposure of 
e n riched progen itor cel ls to both rG M-CSF and r1 L-3 produced additive effects 
on colony format ion .  Coadmin istrat ion of these cytokines resu lted i n  a s ign ificant 
i ncrease in the abso lute number, but not in the percentage, of pure eosi noph i li c  
co lonies compared to  cel ls exposed to either factor alone (e .g . ,  54±3 vs .  27±4 or  
20±2 ; p < . 02 ) .  Sig n i ficant i ncreases were also noted i n  the  number o f  mixed 
macrophage/eosi noph i l  co lon ies .  I n  contrast, o n ly smal l  i ncreases were noted 
in t he  n umber of non-eos inoph i l i c  colo n ies formed u nder  t hese cond i t ions .  
Consequently, enhanced colony format ion i nduced by the combi nat ion of r1L-3 
and rGM-CSF resu lted pri mari ly from the i ncrease i n  pure and mixed eosi nophi l  
colon ies.  A l though the add it ion of  1 00 nM bryostat i n  1 to the combination  of r lL-
3 and rGM-CSF produced no change i n  the total number of colon ies,  it d id result 
in a s ign i ficant reduction  in both the abso lute n umber (e .g . ,  9±3 vs.  54±3 ; p < 
. 0 1 ) and re lative percentage (e . g . ,  7% vs .  48%) of eosi noph i l ic co lon ies ,  with a 
correspondi ng i ncrease i n  the re lative perce ntage and absolute number of pure 
macrophage and mixed neutroph i l -macrophage colon ies. 
In v iew of prev ious studies demonstrat i ng that coadmin i strat ion  of I L-5 
with I L-3  p ri mari ly p ro m otes t he  g rowth of eos i noph i l i c  proge n ito rs , 8 4  
experiments were perfo rmed i n  order to determi ne whether bryostat in  1 cou ld 
b lock th is  process (Table 3 ) .  Coadmi n ist rat ion  of r 1 L-5 and r1L-3 resu lted i n  
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approxi mately 90% eosi nophi l ic colonies.  Coadmin istrat ion of bryostat i n  1 with 
r 1L-5 d id not s ign i ficantly reduce the nu mber of eosinophi l ic colonies ( 1 0±1 vs. 
7±1 , P > .05) but did permit a l i mited number of non-eosi noph i l ic  colonies to 
fo rm. Addit ion of bryostat in  1 to the combi nat ion of r 1L-5 and r1 L-3 sig nificantly 
reduced the  abso lute number  (and percentage) of eos inophi l ic  colon ies when 
compared to r 1 L-3 ( 2± 1 vs.  28±3, p < .00 1 )  o r  r 1L-5 alone (2±1 vs. 1 0±1 , P < .0 1 ) 
o r  i n  combinat ion (2±1 vs.  44±3. P < . 00 1 ) .  Substantial i ncreases i n  the 
abso l ute  n u m ber  (and percentage )  of pu re and m i xed n eutroph i l  and 
macrophage co lon ies were also noted whe n ce l ls  were exposed to bryostat in  1 
i n  conjunct ion with r1 L-3 and r IL-S. 
In sum mary ,  PK-C activators at opti mal dose level selectively stimu lated 
macrop h age  and neut ro p h i l  l i neage g rowth wh i l e  i n h i b i t i ng  eos i n o p h i l  
development .  Th is i n h ibi t ion or  l i neage alte rat ion appeared t o  b e  i n  the  early 
developmental stage of the com itted myelo id progenitor cel ls s i nce bryostatin 1 
fai led to b lock eosi noph i l  differentiat ion i n  cu ltu res with r 1L-5 (a late stage 
eosi noph i l  g row1h  factor) alone . In contrast to the combinat ion of bryostat i n  1 
and r IL-3,  o r  bryostat i n  1 and rGM-CSF,  r 1 L-3 i n  conjunct ion with rG M-CSF 
i nduced majori ty of eosi noph i l ic colon ies.  Th is  may ind icate t hat the  effect of 
b ryostat i n  1 i s  not mediated by the re lease of e i ther G M-CSF or I L-3 f rom 
accessory cells i n  t he  culture.  
3.  Sched u l e  dependence of bryostat i n  1 -medi ated effects o n  r 1 L-3 
s t i m u l ated c o l o n y  f o r mat i o n  I n  v i ew of t he  dua l  act i on  of P K-C 
activators ,schedu led admin i strat ion of  r 1 L-3 and bryostati n 1 was performed to 
defi ne the i nteract ion between these two agents, wh ich were added to the plates 
separated by i ntervals of 0 to 1 44 hours (Table 4). When bryostat in 1 was added 
to the plates at any t ime up to and i ncluding 1 44 hours fol lowi ng r IL-3, a 
Table 3. Effect of Bryostat in  1 o n  the Growth and Lineage Commitment of Myeloid Progen itors 
Exposed to r1L-3 and/or r 1L-5 
Day 1 4  CFU-GM/ 4000 CD34 + cel ls plated 
Sti mu l i  Eos Eos/M M N N/M Total 
r 1L-3 28 ± 3(6 1 ) 1 1  ± 2(24) 5 ± 1 ( 1 1 )  0 2 ± 1 (4 )  46 ± 3 
r 1L-5 1 0  ± 1 ( 1 00)  0 0 0 0 1 0  ± 1 
r 1L-3 + r1 L-5 44 ± 3(75 )  8 ± 1 ( 1 4) 6 ± 2 ( 1 0)  0 1 ± 1 (2) 59 ± 4 
r 1L-5 + Bryo 1 7 ± 1 (4 7 )  1 ± 1 (7) 4 ± 2(27)  1 ± 1 (7 )  2 ± 1 ( 1 3) 1 5  ± 2 
r 1 L-3 + Bryo 1 7 ± 1 ( 7 )  3 ± 1 (3) 34 ± 3(34) 1 5  ± 2 ( 1 5 ) 4 1  ± 1 2 (4 1 )  1 00 ± 1 2  
r 1L-3 + r 1L-5 + Bryo 1 2 ± 1 (2 )  2 ± 1 (2 )  25 ± 3(28)  9 ± 1 ( 1 0) 52 ± 1 3 (58) 90 ± 1 4  
Cel ls were plated i n  the presence of r1 L-3 (50ng/ml )  and/or r 1L-5 (50ng/ml) i n  conjunction  with bryostati n 
1 ( 1 0nM) .  Values represent the means ± SE  for a representative experiment performed i n  tripl icate ; two 
addit ional experiments y ielded essential ly equivalent results. Figu res i n  parentheses correspond to the 
percentage of each colony sub-type relative to the total number of colon ies.  
Abbreviat ions: Eos,  eosinophi l ;  M,  monocyte/macrophage ;  N ,  neutroph i l ,  b ryo 1 ,  bryostat in 1 .  
+:0-
N 
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signi ficant increase i n  the number of colon ies was observed when compared to 
cel ls exposed to r1L-3 alone (94 ±1 6 ,  84±3, or 77±6 vs. 3 1 ±5 ,  P < .0 1  for each 
comparison ) .  In add it ion , except at the 1 44 hour  poi nt , the total number  of 
colonies fo rmed when bryostat in 1 was admin istered after r 1L-3 was equivalent 
to the values obtai ned when factors were added together  at the i n it iat ion of 
cu ltu res .  Si m i lar ly ,  a decrease in the fract ion  and abso lute n u mber  of  
eosi noph i l ic  co lon ies ,  and a correspondi ng i ncrease i n  the percentage of non­
eosi noph i l ic  co lon ies ,  was observed when bryostat i n  1 was added with i n  1 20 
hours fol lowing add it ion of the r IL-3. When addit ion of bryostat in  1 was de layed 
beyond 1 20 hours ,  the reduct ion in the number  of eosi noph i l ic  co lon ies was 
abrogated,  suggest i ng  that a su bpopu lat i on  of hematopoiet ic  p rogenitors 
exposed to r 1L-3 had become committed to the eosinophi l ic l i neage at th is  t ime.  
A diffe rent response pattern was noted to when bryostat i n  1 was added 
prior  to r IL-3.  U nder these co ndit i ons,  addit ion of r 1L-3 to the cultures 4 hours 
fo l lowi ng bryostat in  1 resu lted i n  colony fo rmation  equivalent to that observed 
when t hese agents were added si mu ltaneously (e .g . ,  89±9 vs. 89±3) .  However, 
when the i nterval between bryostat in  1 and r 1L-3 admin i strat ion was i ncreased to 
24 hou rs, colony format ion  was s ign i f icant ly reduced co mpared to ce l ls  
s imu ltaneously exposed to these agents (50±? vs .  89±3 ; p < .0 1 ) .  Neverthe less, 
s ignif icant reduct ions i n  the number and percentage of eos inoph i l ic  colon ies ( 
1 2±3 vs .  24±3, P < .05) ,  and i ncreases i n  the n umbers of pu re and m i xed 
neutroph i l  co lon ies persisted . A lthoug h a 72 hour  de lay in addi t ion of  r 1 L-3 
resu lted i n  a fu rther decl i ne  in colony fo rmati on to levels equ ivalent to those 
stimu lated by r 1 L-3 alone,  the percentage and absolute number of eosinophi l ic 
co lon ies remained significantly reduced (?±2 vs. 24±3, P < . 0 1 ) compared to r lL-
3 t reated cel ls. 
Together, these fi ndi ngs demonstrate that events occur shortly after 
Table 4 .  Effect of  Alternative Schedules of  r 1 L-3 and Bryostatin 1 Admin istration on the 
Growth and Li neage Commitment of  Myeloid Progenitors 
t ime of delay (h rs) + Day 1 4  CFU-GM/ 4000 CD34 cells plated 
bryo 1 r1L-3 Eos Eos/M M N N/M Total 
0 24 ± 3 ( 77 )  5 ± 1 ( 1 6) 2 ± 2 ( 7 )  0 0 3 1  ± 5 
0 0 1 3  ± 2 ( 1 5 )  3 ± 1 (3 )  4 1  ± 3 (46)  1 2  ± 3 ( 1 3) 20 ± 1 (22 )  89 ± 3 
2 4  0 1 3  ± 2 ( 1 4 ) 3 ± 1 (3 )  4 1  ± 9(44 )  1 7  ± 3 ( 1 8)  22 ± 1 ( 23) 94 ± 1 6  
1 2 0 0 39 ± 1 (46 )  5 ± 2(6 )  20 ± 1 (24)  1 1  ± 2 ( 1 3) 9 ± 2 ( 1 1 )  84 ± 3 
1 4 4 0 25 ± 1 (32 )  4 ± 2 (5 )  20 ± 4 ( 26 )  1 3  ± 4 ( 1 7) 1 5  ± 3 ( 1 9) 77 ± 6 
0 4 1 4  ± 5 ( 1 6) 2 ± 1 (2 )  43 ± 6 ( 4 8 )  1 0  ± 2 ( 1 1 )  20 ± 1 ( 22)  89 ± 9 
0 2 4  1 2  ± 3(24 )  4 ± 2(8 )  22 ± 5(44 )  4 ± 1 ( 8 )  8 ± 1 ( 1 6) 50 ± 7 
0 7 2  7 ± 2 ( 30 )  0 1 1  ± 3 ( 4 8 )  3 ± 1 ( 1 3) 2 ± 1 (9 )  23  ± 3 
Cel ls were plated i n  the presence of bryostat in 1 ( 1 00 nM)  prior to, i n  conjunction with, o r  following addition 
of r1 L-3 (SOng/ml )  as described i n  the text. Values represent the means ± SE for a representative 
experiment performed in trip l icate ; 2 addit ional experi ments y ie lded essentially equivalent results. Figu res 
in parentheses correspond to the percentage of each colony sub-type relative to the total number of 
colonies. Abbreviations :  Eos, eosinoph i l ;  M, monocyte/macrophage ;  N, neutroph i l ;  bry0 1 , bryostatin 1 .  
� 
� 
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admin ist ration of bryostat in  1 that requ i re the simu ltaneous presence of r 1 L-3 for 
opt i mal enhancement of progenitor ce l l  g rowth .  Furthermore, perturbat ions in the 
tempora l  coordi nat ion of signals induced by bryostat in  1 and r 1 L-3 appear to 
exert d ivergent effects on  the pro l i ferat ive capacity and l i neage commitment of 
these hematopoietic progenitor ce l ls .  
4 .  B ryosta t i n  1 m o d u l ates G M-CSF/ I L-3 f u s i o n  prot e i n  (p IXY321 ) 
induced CFU-G M Previous stud ies showed that p lXY32 1 was more potent 
than the combinat ion of native GM-CSF and I L-3 when compared at suboptimal 
dose leve l in in vitro colony format ion assays.48 No i nformat ion  was avai lable 
conce rning the efficacy (maximal effect) and l i neage specificity of this hybrik ine 
compared to that of native GM-CSF and IL-3 adm in istered at satu rat ing dose 
leve ls .  To address th is i ssue ,  i ndepende nt exper iments were performed 
examin i ng  the CFU-GM i nduci ng capacity and l i neage specif icity of  p lXY321 , 
and comparisons made with the nat ive form of rG M-CSF and r 1L-3 ,  both 
adm i n i stered at saturat ing  levels .  When adm in i stered at the opt imal  leve ls ,  
p l XY32 1 i nduced equ iva lent  nu mbers of total  C FU-G M compared to the  
combinat ion  of r 1L-3 and rG M-CSF at the satu rat ing  dose leve ls  ( Fig . 1 0) .  
B ryostat i n  1 adm i n istered at opt ima l  dose leve l  ( 1 - 1 00nM)  s i g n i ficant ly 
enhanced the total number of CFU-GM, general ly by at least 50%, compared to 
colony formation  st imu lated by opt imal levels of rGM-CSF and r 1L-3 or p lXY321 
( Table 5) .  It should be noted that these i ncreases were less than those observed 
when bryostati n 1 was combi ned with rGM-CSF 1 26 or  r 1L-3 ,  where 1 00-200% 
i ncreases was regu larly observed. The resu lts from the l i neage characterizat ion 
study (F ig .  1 1 )  demonst rated that l i ke rG M-CSF and r1 L-3, p lXY321  induced a 
majority of eosi noph i l  co lon ies (60% of total colon ies) . Bryostat in  1 se lectively 
st imu lated co lon ies of the monocyte/macrophage and neutrophi l ic l ineage, whi le 
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Figu re 1 0 . Dose response cu rve for p 1XY321 . 
4000 CD34+ cel ls/1 ml wel l  were plated i n  the presence of 
various cytokines. After 1 4  day's i ncubat ion ,  co lonies were 
scored. Values represent the mean±SD for tri pl icate cultures 
from one representative experi ment .  One addit ional 
experi ment showed consistent result .  
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i n h ibit i ng  co lon ies of the eosi noph i l ic  l i neage. I n  the presence of p 1XY321 , the 
li neage pattern i nduced by bryostat in  1 was dose related. With 1 nM bryostat i n  1 ,  
there was a 60% i n h ib it io n of eosi noph i l  colon ies (26±3 vs.  6 1 ±5, P < .0 1 ) and 
when bryostat i n  1 was added at 1 0  nM, there was a v i rtua l  abrogat ion  of 
eosi noph i l  g rowth (2±1 vs.  6 1 ±5 ,  p<.001 ) .  With respect to l i neage speci ficity of 
e nhanced g rowth ,  1 nM bryostat in  1 preferent ial ly stimu lated neut roph i l  l i neage 
growth (40±2 vs.  6±3, P < .001 ) with l i ttle effect on  macrophage co lony formation  
(22±5 vs .  9±2, P > . 05 ) ,  whe reas 1 0  n M  bryostat in  1 se lect ively st i m u lated 
co lonies of the macrophage/ monocyte l i neage (51 ±3 vs. 9±2, P < .001 ) ,  with no 
effect on neutroph i l  l i neage g rowth (4±1 vs. 6±3) .  This observat ion suggests that 
1 )  at saturat ing concentrat ions,  p lXY321 exerts co lony stimu lating activity toward 
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Table 5 .  Effect of Bryostat in  1 on day 1 4  CFU-GM I nduced by p lXY321 
or rIL-3/rGM-CSF Combinat ion 
bryostat in  1 nM 
G rowth 
Factors exp# 0 0 . 5  1 . 0  1 0  1 0 0 
p lXY321 42 ± 8 57 ± 1 *  56 ± 8 69 ± 9 * 81  ± 22 • 
2 1 02 ± 1 0  1 39 ± 7 ·  1 63 ± 1 2 ·  1 1 5 ± 1 1  1 2 1  ± 1 3  
3 29 ± 4 57 ± 5 *  72 ± 9 ·  77 ± 1 4 ·  44 ± 3 • 
4 72 ± 8 1 20 ± 1 2 ·  1 2 1 ± 3 • 1 26 ± 4 ·  1 4 1  ± 1 9  • 
5 90 ± 9 94 ± 6 1 25 ± 1 2 ·  1 33 ± 1 3 ·  1 44 ± 1 7  • 
6 1 8 1 ± 2 1  253 ± 22 * 262 ± 20 · 287 ± 3 ·  248 ± 1 2  • 
7 1 50 ± 1 9  ND 205 ± 1 9  * ND 207 ± 8 • 
r IL-3+ 35 ± 6 63 ± 6 * 65 ± 7 * 58 ± 3 * 5 1  ± 1 2  * 
rGM-CSF 2 1 00 ± 1 1  1 25 ± 2 1  1 42 ± 1 7  • 1 43 ± 1 9  * 1 65 ± 9 • 
3 39 ± 6 65 ± 8 * 66 ± 9 * 6 1  ± 1 0  * 37 ± 1 
Values represent mean ± SD (trip l icate) of day 1 4  CFU-GM/ 4000 CD34+ celis 
for each experiment. A Student's t-test was applied for the comparisons 
between g roups. Cytokine concentrat ion : p 1XY321 , 1 0-2Sng/m l ;  r IL-3, SOng/ml ;  
rGM-CSF SOng/m l .  
* sign ificantly g reater than values for  the combinat ion of r 1L-3 and rGM-CSF 
or  p lXY321 alone (p < 0 .05) .  
C D34+ myelo id progen itor  ce l ls s im i lar to that achieved by the combi nat ion of 
opt imal concentrat ions of the native form of GM-CSF and I L-3 with repective to 
both co lony format ion and l i neage specif icity ; 2 )  The pote nt iat i ng  effect of 
bryostat in 1 is u n l ikely to be mediated sole ly by the re lease of either IL-3 or  GM­
CSF by residual accessory cel ls present i n  the cu ltu res s i nce enhancement of  
g rowth conti nued to be observed i n  the presence of saturat ing levels of I L-3 and 
G M-CSF together  with bryostat in  1 ;  3) bryostat i n 1 exerts d iverse l i neage 
modu lat ing effects, and these effects appear to be dose-related. 
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Figure 1 1 . Effect of bryostat in  1 on  l ineage commitment of CD34+ myeloid progen itors 
exposed to p lXY321 and rG M-CSF/rI L-3. CD34+ bone marrow cells (4000/1 ml wel l )  
were cu ltu red i n  the presence of various cytoki nes ( r IL-3 SOng/ml ,  rG M-CSF SOng/ml ,  
p lXY321 2Sng/ml )  i n  conjunct ion with bryostat in  1 .  Data were expressed as the mean 
±SE from one representative experiment performed in tripl icate ; five additional 
experiments y ie lded essentially sim i lar resu lts . 
Abbreviat ions :  eos . ,  eosinoph i l ;  neu . ,  neutroph i l ;  mac. , macrophage. 
• significantly less than values for g rowth factor(s) alone (p  < .02) .  
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5. B ryostat i n  1 acts d i rect ly  on isolated CD34+ myelo id  progenitor 
c e l l s  Because of possible residual accessory cel is i n  the iso lated CD34+ cel i  
populat ion ,  a major issue to be resolved is whether PK-C activators act di rect ly 
o n  CD34+ myelo id progen i tor  ce l is ,  o r  i nd i rect ly  by sti mu lat i ng re lease of  
secondary HGFs in  the  culture. 1 24 , 1 25 To test t h i s  possib i l i ty, l i miti ng d i lution ,  
exogenous  rep lace ment ,  and  n e ut ra l i z i ng  ant i body stud ies  h ave been  
employed. 
As shown in the experi ment i l lust rated in Fig. 1 2A,  when CD34+ cel is 
were plated at density as low as 62/ml in the presence of rGM-CSF, bryostati n 1 
gave rise to a h igher  average nu mber of co lon ies t han those exposed to rGM­
CSF alone. However, the large variat ion in the quadrupl icate cu ltu res at low ce l l  
density made these difference statistically i ns ign ificant. The  same was t rue i n  t he  
case of  r 1 L-3 (F i g .  1 28) .  Addi t ional  experiments were performed employ ing 
p 1XY321 .  I n  these experi ments bryostat in  1 fai led to stimu late co lony format ion 
when CD34+ ce l ls  were plated i n  dens it ies less than 250/m l .  However, in  such 
experi ments the l i neage alterat ion (e . g . ,  the i n h i bi t ion of eosi noph i l ic co lon ies) 
by b ryostat i n  1 was persistent even at lowest cel l  density (F ig .  1 3) .  These 
fi ndings suggest that the l i neage alterat ion i nduced by bryostat in 1 i s  l ike ly to be, 
at least in part, mediated by di rect act ions on  progenitor ce l ls ,  s i nce the l i neage 
alterat ion  persisted in cultures plated at extremely low ce l l  densit ies. 
To address th is  i sssue further, the effects of rG-CSF, a major neutroph i l  
g rowth factor, and rCSF- 1 ,  a major macrophage growth factor, were evaluated i n  
combinat ion  with p lXY321  i n  order to defi ne whether t he  growth and  phenotypic 
alterat ions i nduced by bryostat in  1 could be the result of, o r  m i micked by, other 
hematopoietic g rowth factors e laborated i n  the cultures (F ig .  1 4) .  The addit ion of 
opt i mal  co lony st i m u lat i ng  concentrat i ons  of e i ther  rG-CSF or rCS F- 1  i n  
conjunction with p lXY32 1 i ncreased the total number of co lon ies to levels sim i lar 
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Figure 1 2 . Limit ing d i lut ion culture of CD34+ myeloid progenitor ce l ls .  
CD34+ cel ls were plated at various cel l  densities i n  soft agar cu ltures. 
Values represent the mean±SE % of control (day 1 4  CFU-GM i nduced 
by g rowth factor alone) for one experiment performed in quadrupl icate. 
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Figu re 1 3. Li neage commitment of CD34+ myeloid progenitors in l im it ing 
di lutio n  cultures. CD34+ cel ls (from 4000 to 60 ce l ls/wel l/m l)  were p lated in 
the presence of p lXY32 1 ( 1 0ng/ml)  a lone or i n  combi nat ion with bryostati n 
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1 ( 1  OnM) .  Data were expressed as the mean±SE of eosi nophi l  colony 
percentage of total CFU-GM from one representative experiment performed 
in quadru plicate.  One add it ional experiment y ie lded equivalent results. 
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Figu re 1 4 . Effects of exogenous rep lacement by rG-CSF and 
rCS F- 1 o n  p lXY321 -i nduced l i neage commitment .  CD34+ bone 
m arrow ce l l s  (4000/ 1  ml wel l )  were cu ltrued i n  semiso l id 
agar medium with 20% fetal bov i ne serum fo r 1 4  days. 
Values represent  mean±S D of tr ip l icate cultures  for o n e  
representative experiment .  Th ree add it ion al exper iments 
y ie lded essent ia l ly equ ivalent resu lts. Concentration  of 
experimen ta l  agen ts are : p lXY321 1 O ng/ml ;  rG-CSF 50u/m l ;  
rCS F- 1  1 00 ng/m l ;  bryostat in  1 1 0n M .  Abbreviation s :  Eos . ,  
eos inoph i l ;  Mac . ,  macrophag e ;  Neu . ,  Neutroph i l ;  Bryo 1 ,  
bryostati n 1 .  
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to those ach ieved with 1 0  nM bryostat i n  1 .  The dist ri but ion of co lony subtypes, 
however ,  was stri k i ngly d i fferent u nder each condit io n .  Fo r example ,  rG-CSF, 
w h e n  ad m i n i stered a lo n e  o r  in combi nat i on  wi th  p 1 XY32 1 , exc lus ive ly  
augmented neutroph i l  co lony format ion (53±20 vs .  1 ±1 , P < .02)  whereas rCSF-
1 selectively i ncreased the number of macrophage colonies (86±32 vs.  2 1 12 ,  P 
< . 05 ) .  The t rip le  combi nat ion  of p 1XY32 1 , rG-CSF ,  and rCSF-1  produced 
substant ia l ly more colon ies than any of the two agent combi nations ,  and the 
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addit ional  colon ies consisted of cel ls exh ibi t i ng neutroph i l , macrophage,  and 
neutroph i l/macrophage m ixed chacte ristics. These percentages were s imi lar to 
t hose observed i n  cel ls exposed to the combinat ion of  1 0n M  bryostati n 1 and 
p 1 XY32 1 . I n  contrast to the effects observed wi th  1 0n M  bryostati n 1 ,  however, 
neither  rG-CSF nor rCSF-1 (nor  the combinat ion of both)  i n h ibited the number  of 
eosinoph i l ic colonies i nduced by p 1XY32 1 . This resu lt i ndicates that G-CSF and 
CSF-1 are un l ikely to play a ro le in mediati ng the abi l ity of bryostat i n  1 to i nh ibit 
eosinophi l ic  cOlony format ion .  
To exclude the possi b l i ty that the  co lony en hanci ng prope rt i es  of 
bryostat i n  1 on  p l XY32 1 i nduced hematopoiet ic g rowt h  represented ind i rect 
act ions of G-CSF or CSF- 1 released by residual accessory cel ls sti mu lated by 
bryostat in 1 ,  neutral iz ing antibod ies were employed. As depicted in  Fig. 1 5, anti­
G - C S F  se lect i ve l y  b locked n e ut roph i l  (0  vs .  90± 1 6 ,  P < . 00 1 ) and 
neutrophi l/macrophage mixed colon ies (7±3 vs .  36±6, P < . 0 1 ) stimu lated by  the  
combi nat ion of p lXY321 and rG-CSF ( 1 5B) .  On the o ther  hand ,  ant i-CSF- 1 
se lectively b locked macrophage colony growth (6±4 vs.  52±9, P < . 0 1 ) i nduced 
by the combi nat ion of p lXY32 1 and rCSF- 1 ( 1 5C) .  However, i n  the  presence of 
the  combinat ion of p lXY321 and bryostat in  1 ,  both neutral iz i ng antibodies e i ther 
alone or  i n  combi nation fai led to b lock the i ncrease i n  pure o r  m ixed neutroph i l  
and macrophage colony format io n ,  i n  contrast to  the results of  studies i n  which 
exogenous rG-CSF or  rCSF-1  were added to the cu ltu res ( 1 50) .  This f ind ing 
strong ly  suggests that secondary re leases of G-CSF and CSF- 1 are not 
primari ly responsible for the effects of bryostati n 1 on the l i neage commitment of 
C034+ ce l ls  exposed to p lXY321 , a lthough the possib le contri bution  of other  
g rowth factors,  such as IL- 1 , I L-6, can not be excluded at th is  t ime. 
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Figure 1 5. Effects of G-CSF and CSF-1 neutralizing antibodies on l ineage commitment of CD34+ myeloid progenitors.CD34+ bone marrow 
cel ls (4000/1 ml well) were cultured in semisolid agar medium with 20% fetal bovine serum for 1 4  days. Colonies were scored and characterized 
cytochemically in situ as described. Values represent mean±SD of tripl icate cultures from one representative experiment. One additional 
experiment with rCSF-1 neutralizing antibody yielded essentially equivalent results. Concentration of experimental agents are: plXY321 
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6. The no n-active phorbol  ester, 4 ex -POD, exerts no  effect on  the 
g rowth and l i neage  c o m m i t m e n t  of  i s o l ated C 0 34+ mye l o id 
progenitor cel l s  exposed to r 1 L-3 or p lXY321 To determ i n e  whether the 
effects of PK-C act ivators on  CFU-G M formation i nduced by r 1 L-3 or  p l XY321 
were i ndeed mediated t h rough PK-C act ivat i on ,  4 ex - P D D ,  a n on - P K-C 
st i m u lat ing  phorbol  ester ,  which has a structu re s im i lar  to PDBu , 1 43 was 
coad m i nistered with r 1 L-3 ( Fig . 1 6 ) .  In contrast to PDBu ,  4 ex -PDD ne i ther  
e nhanced CFU-GM format ion nor  i nduced the l ineage alte rat ion i n  conju nct ion 
wi th  rI L-3. The experi ment with p lXY32 1 yie lded simi lar results (data not  shown) .  
Th is  result ,  i n  conjuncti on  with the  observat ion that th ree PK-C activators with 
d ifferent b io log ical activ it ies i nduced si mi lar responses, strong ly suggests that 
PK-C perturbat ion is i nvo lved in mediati ng the enhancement of co lony format ion 
and l i neage alterat ion by these agents. 
7. B ry o st at i n  1 m o d u l a tes  rSCF/ p l X Y 3 2 1  i n d uced  C F U - G M  
format i o n  SCF has been shown t o  exert strong synerg ist ic effects on  mu lt i ­
l i neage co lony format ion when admin istered in conjunct ion  with I L-3  and GM­
CSF or  p 1 XY32 1 . 5 1  ,7 1  ,73,74 One recent report demonstrated that SCF i nduces 
rapid tyrosi ne  phosphorylat ion of P LCy, which coore lates with its activation .aa 
This fi nd ing ind icates that PK-C aciv i t iy may i nvolve SCF sig nal t ransductio n  
s i nce PLCy act ivat ion  generates DG ,  a phys io log ical PK-C act ivator ,  b y  
hydrolyzi ng membrane phospho l i p id ,  P I P2 .  To determine whether SCF, a s  a 
PLCy activator, m imics the effect of bryostat in  1 i n  stimu lati ng colony formation in 
vitro, rSCF was coadm in i stered with p 1XY321 . rSCF a lone fai led to support 
colony growth .  However, the combinat ion  of rSCF and p l XY32 1 en hanced total 
CFU-GM format ion ,  compared to p lXY32 1 alone,  to vary ing degrees averaging 
1 44% ( range 28-288%, n=4)  (Table 6) .This enhancement preferential ly i nvolved 
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Figure 1 6. The effect of non PK-C stimulating phorbol ester, 4 a-POD, on the CFU-GM formation induced by r IL-3. C034+ cells 
were exposed to POBu or 4a-POO in conjunction with 50 units/ml r I L-3, and the number of day 1 4  CFU-GM determined. Values 
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Table 6 .  Effect of Bryostat in  1 on  Day 1 4  CFU-GM Induced by rSCF, 
p lXY321 and Other Myeloid Growth Factors 
bryostat in 1 nM 
G rowth  Factors exp# 
0 1 . 0 1 0 
plXY321 * 1 5 1  ± 1 2  I'D I'D 
* 2 4 1  ± 4 I'D I'D 
3 6 1  ± 1 2  I'D I'D 
5 80 ± 1 3  I'D 1 22 ± 6 t 
p lXY32 1 HSCF * 1 1 44 ± 1 5  t 1 92 ± 22 :j: 253 ± 35 :j: 
* 2  1 59 ± 2 1  t 209 ± 1 7 :j:  242 ± 2 1  :j: 
3 78 ± 7 I'D 1 69 ± 1 3 :j: 
4 1 27 ± 37 282 ± 1 5  :j: 270 ± 1 4  :j: 
5 1 4 1 ± 5 t 234 ± 2 1  :j: 2 1 0 ± 24 :j: 
p lXY32 1 HSCF * 1 252 ± 27 :j: 282 ± 4 323 ± 7 § 
HG-CSFHCSF- 1 * 2 1 89 ± 1 1  27 1  ± 49 § 33 1  ± 38 § 
3 1 36 ± 1 1  :j: I'D I'D 
4 3 1 5 ± 1 4 :j:  I'D I'D 
Values represent mean ± SD (t r ipl icate) of day 1 4  CFU-GMI 2000 or  4000 
CD34+ ce l ls for each experi ment. Student's t-test was appl ied for the 
comparisons between groups. Cytoki ne concentrat ion : p 1XY321 , 1 0ng/m l ;  
rSCF, 1 00ng/m l ;  rG-CSF, 50un i tlm l ;  rCSF- 1 ,  1 00ng/m l 
t sign i ficantly greater than values for p lXY32 1 alone (p < .02) .  
:j: sign i ficantly greater than values for the combi nat ion of p lXY32 1 and 
SCF (p < .05) .  
§ s ignificantly greater than va lues for the combi nat ion of p 1XY32 1 , rSCF, 
rG-CSF and rCSF- 1 (p < .05) . 
* E xperiments were pe rformed with 2000 CD34+ cel ls/1  m l  wel l .  
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neutroph i l  (36±5 vs. 0 ,  P < . 0 1 ; 59±1 6 vs. 1 ±2 ,  P < .05) ,  eosi noph i l  (60± 1 3  vs. 
37±1 1 ,  P < . 0 1 , 38±5 vs. 27±5, P < . 0 1 ) and neutroph i l/macrophage m ixed (28±6 
vs. 2±2 , P < .05) l i neages, as i l l ustrated by the representative experi ments 
shown i n  Table 7. These results contrast with those previously described for the 
combinat ion of p lXY32 1 and bryostat i n  1 (Fig.  1 1 ) ,  where bryostat i n  1 exh i bited 
a dose-depe ndent i n h i bitory effect on eosi noph i l  co lony format ion .  This f ind ing 
suggests that the effect of bryostat in  1 in  potentiati ng p lXY32 1 - i nduced co lony 
formation  i s  not identical to that of exogenous SCF si nce coadmin i st rat ion of 
rSCF with p lXY321  fai led to m im ic the i n h i b i tory effect of b ryostat i n  1 o n  
eos inoph i l ic deve lopment .  To fu rther  conf i rm t h i s  f i nd i ng ,  b ryostat i n  1 was 
coadmin istered with rSCF and p 1XY321 . The total number of CFU -GM stimu lated 
by rSCF and p lXY32 1 was i ncreased fu rther  by an average of 63% ( range 31 -
1 22%, n=4) at 1 n M  and an average of 8 1 %  (range 49- 1 1 6%, n=5) at 1 0nM 
respectively when bryostat i n  1 was i nco rporated i nto the  cu l ture (Table 6 ) .  
Cons istent with prev ious f ind ings i n  t he  studies i nvolving  r IL-3 ,  rGM-CSF and 
p 1XY32 1 , bryostat in  1 selectively sti mu lated macrophage co lony format ion  at 1 -
1 0  n M  and i n h ib ited eosi noph i l  co lony g rowth i nduced by the combinat ion of  
p lXY32 1 and rSCF (Table 7) . These observat ions suggest that PK-C activity 
might be i nvolved in regu lat i ng the g rowth and l ineage commitment of myeloid 
progen i to r  ce l ls at a re latively early developmental stage,  or, alternat ively,  that 
rSCF mobi l izes more pri mit ive progen itor or  stem ce l ls  i nto cel l  cycle and 
renders them more respons ive to bryostat in  1 and p 1XY32 1 . These fi ndings also 
i mply that bryostat i n  1 acts di rect ly on myeloid progen itor cel ls ,  rather  than 
sti mu lat ing residual accessory ce l ls to  re lease SCF i n  the culture.  
To fu rther evaluate whether the colony-enhancing effect of bryostat in 1 
could be abrogated by admin i steri ng rG-CSF and rCSF- 1  together  with rSCF 
and p 1XY32 1 , add it ional experi ments i nvolvi ng those g rowth factors were 
Table 7. Effect of bryostatin 1 on  the Li neage Commitment of CD34+ Myeloid Progenitors 
Exposed to p lXY321 and rSCF 
Da� 1 4  CFU-GM 12000-4000 CD34+ cel ls 
St imu l i  Eos Eos/M M N N/M Total 
EXQ. 1 .(4QQQ QQ34± (;�IISIw�lIl 
plXY321 37 ± 1 1 (47) 1 2  ± 7( 1 5) 26 ± 2(33) 0 4 ± 1 (5) 79 ± 1 3  
plXY321 HSCF 60 ± 1 3(43) 
* 
1 1  ± 5(8) 20 ± 3 ( 1 4) * 36 ± 5(25) * 1 4 ± 7( 1 0) 1 41 ± 5 * 
plXY321 HSCF+Bryo 1 1 nM 30 ± 6 ( 1 3) t 8 ±  6(4) 43 ± 9( 1 8) t 63 ± 23(27) 90 ± 1 3(38) t 234 ± 21 t 
t o t plXY321 HSCF+Bryo 1 1 0  nM 2 ± 1 ( 1 )  1 60 ± 1 4 (77) 
t 8 ± 6(4) t 37 ± 24( 1 8) 2 1 0 ± 24 t 
EXQ. 2. (2QQQ QD34± (;�IISlw�lIl 
plXY321 27 ± 5(53) 1 ± 1 (2) 20 ± 8(39) 1 ± 2(2) 2 ± 2(4) 51 ± 1 2  
plXY321 HSCF 38 ± 5(26) * 7 ± 3(5) * 1 2  ± 2(8) 59 ± 1 6(42) * 28 ± 6( 1 9) * 1 44 ± 1 5 * 
plXY321 HSCF+Bryo 1 0 . 1  nM 20 ± 4( 1 6) 5 ± 2(4) 33 ± 4(26) 37 ± 2(29) 33 ± 1 6(25) 1 28 ± 1 9  
plXY321 HSCF+Bryo 1 1 nM 9 ±  5(5) 4 ±3(2) 77 ± 22(40) 40 ± 1 0(21 ) 62 ± 1 0(32) 1 92 ± 22 t 
plXY321 HSCF+Bryo 1 1 0  nM 8 ± 2(3) t 4 ± 2(2) 205 ± 27(8 1 )  
t 1 ± 1 (O) t 36 ± 7( 1 4) 254 ± 35 t 
Values represent the means ± SD for each representative experiment performed in triplicate. Three additional experi ments yielded 
similar results. The Student's t-test was applied for comparisons between groups. Figures in parentheses correspond to the 
percentage of each colony sub-type relative to the total number of colonies. Abbreviations: Eos, eosinophil; M, monocy1el 
macrophage; N, neutrophi l ;  bryo 1 ,  bryostatin 1 .  Concentrations of experimental agents: p1XY321 ,  1 Onglml; rSCF,  1 00ng/ml. 
* significantly greater or less than values for piXY alone (p < 0 .05) . 
t significantly greater or less than values for the combination of plXY321 and rSCF (p < 0.05) .  
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performed. When rG-CSF and rCSF- 1 were combi ned with rSCF and p 1XY32 1 ,  
total  C FU-GM format ion  i ncreased variably (compared to rSCF+pIXY32 1 ) , 
averagi ng 79% ( range 1 8- 1 48%, n=4, p < .05 i n  t h ree experi ments) (Table 6 ) .  
Th is  com bi nat ion  i nduced a majo rity o f  colon ies d i sp lay ing neut roph i l  and 
macrophage characte ristics (Table 8) .  I n  the experiments shown in  Table 8 ,  1 0  
n M  bryostat i n  1 further  enhanced the total nu mber of CFU-G M induced by mu lt i ­
factor combinat ions by 28 and 74% i n  two experments (p < . 05 i n  each case) 
respective ly ,  with a majority of co lon ies exh ibit i ng macrophage characteristics 
(Table 8). Furthermore ,  the nu mber of eosi noph i l ic  co lon ies was s ign i ficantly 
reduced in t he presence of bryostat in 1 .  These fi ndings demonstrate that rG-CSF 
and rCSF- 1  do not mimic the effects of bryostat in 1 on colony format ion i nduced 
by the combinat ion of rSCF and p 1XY321 , si nce addit ion of both of these growth  
factors fai led to  prevent bryostat in 1 from sti mulat i ng CFU-GM format ion induced 
by rSCF and p l XY32 1 or to i n h i b i t  the g rowth of eosi noph i l ic  co lon ies .  The 
f inding that the combinat ion of bryostat in 1 with rSCF, p iXY, rG-CSF, and rCSF-
1 i nduced  max i mal  g rowt h of  macro phage c o l o n i e s , suggests  t hat 
p harmaco logical  manipu lat ion at the level of PK-C mig ht se lective ly en hance 
the g rowth and commitment of myeloid progen itor ce l ls of th is  specific l i neage in 
the presence of mu lti ple i nteract ing cytokines. 
8. B r yostat i n  1 i n h i b i t s  p l X Y3 2 1 / r Epo  or rSCF/p l X Y 3 2 1  I rEpo  
i nd u ced B FU-E  and CFU-G EMM format ion  Si nce the resu lts o f  p revious 
studies i ndicate that PK-C activity may be i nvolved in  regu lat i ng the g rowth and 
d i fferentiat ion of myeloid progenitors in early hematopoietic stages, CFU-GEMM 
and BFU-E assays we re performed to exp lore whether bryostat in  1 might also 
e n h ance the g rowth and d i f ferent iat ion of ea rly eryt h ro id and mu lt i pote nt 
progen itor cel ls . l n  experiments performed in methylce l lu lose medium contai n ing 
Table 8. Effect of Bryostatin 1 on Growth and Lineage Commitment of CD34+ Myeloid Progenitors 
Exposed to Myeloid Growth Factors 
Sti mu l i  Day 14  CFU-GMI 2000 CD34+ cells 
exp# Eos Eos/M M t:lI I:lILM 
plXY321 +rSCF 1 2  ± 3(8) 4 ± 2(2) 29 ± 4(20) 50 ± 24(32) 59 ± 8(38) 
2 38 ± 5(26) 7 ± 3(5) 1 2  ± 2(8) 59 ± 1 6(4 1 )  28 ± 6( 1 9) 
plXY321 +rSC F+rG-CSF 21  ± 5 ( 1 1 )  6 ± 2(3) 73 ± 1 2(39)
* 27 ± 3 ( 1 4) 62 ± 1 7(33) 
+ rCSF-1 * 
60 ± 7(24)* 73 ± 1 5(29)* 2 25 ± 4( 1 0) 1 0  ± 5(4) 84 ± 9(33)* 
plXY32 1 +rSCF+rG-CSF 1 2  ± 1 (4) 5 ± 2(2) 
t 
38 ± 3( 1 4)t 1 47 ± 25(54) 68 ± 21 (26) 
+rCSF-1 + bryo 1 1 nM t 
2 1 5  ± 4(5) 5 ± 3(2) 1 1 9 ± 1 3(42) 62 ± 1 1  (22) 8 1  ± 6(29) 
plXY321 +rSCF+rG-CSF 3 ± 3( 1 { o t 3 1 6 ± 36(96{ 1 ± 1 (0)t 1 0  ± 1 (3)t 
+rCSF-1 + bryo 1 1 0nM t 2 ± 0(0) 
t 
287 ± 1 1  (89)t o t 2 3 ± 1 ( 1 )  3 1  ± 5(1  O)t 
Values represent the means ± SD (triplicate) for each experiment. The Student's t-test was applied for 
comparisons. Figures in parentheses correspond to the percentage of each colony sub-type relative to 
the total number of colonies. Abbreviations: Eos, eosinophil ;  M ,  monocyte/macrophage ; N, neutrophil ; 
bryo 1 ,  bryostatin 1 .  Concentrations of experimental agents: plXY321 ,  1 Ong/ml ;  rSCF, 1 00ng/ml; 
rG-CSF, 50uniUml; rCSF- 1 ,  1 00ng/ml. 
* significantly greater or less than values for the combination of piXY and rSCF (p < 0.05). 
Total 
1 54 ± 2 1  
1 44 ± 15  
1 89 ± 1 1  * 
252 ± 27 * 
270 ± 49 t 
282 ± 4 
330 ± 38 t 
323 ± 7 
t 
t significantly greater or less than values for the combination of plXY321 , rSCF, rG-CSF and rCSF-1 (p < 0.05). 
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human serum ,  p lXY32 1 admin istered i n  conjunct ion with human rEpo effectively 
stim u lated eryth roid (BFU-E)  and eryth roid/myeloid mi xed (CFU-GEMM) co lony 
fo rmat ion .  In contrast to effects observed on  myeloid progenitors,  however, 
bryostati n  1 d id not enhance the number of p lXY32 1 stimu lated BFU-E or  CFU­
G E M M  at a doses of 0 .05  nM to 1 00 n M .  I nstead , it resu lted in 50-83% 
decreases in the number of those colonies when admin istered at doses of 1 0  to 
1 00 n M  (Table 9 ) .  In add i t iona l  experiments i nvo lvi ng  the  rSCF/pIXY/rEpo 
com bi nat i o n ,  wh ich were performed in agar medium contai n i ng  no h u man 
serum ,  it was observed that bryostat in  1 also i nh ib ited BFU-E and CFU-GEMM 
format ion at  the same dose range (Table 1 0) .  Th is  data suggests t hat bryostat in  
1 ,  when cont i nuously present i n  the cu ltures, m ight exert specif ic i n h i b i tory 
effects o n  eryth ro id l i neage growth ,  e i ther by i nh ib it i ng eryth ro id d iffe rent iat ion  
and/o r by i nducing mu lt ipotent proge n itor ce l l s  to  commi t  towards colon ies of  
non-eryth roid l i neages.  Thus,  the i n h ib itory effects of conti nuously admin iste red 
bryostat i n  1 toward h u man erythro id progen i to rs may be si m i lar  to those 
previously described fo r certai n  myeloid progen itors (e .g . ,  those of eosi noph i l ic 
o rig i n ) .  
Table 9. Effect of Bryostat in  1 on  the Growth and Lineage Commitment 
of Mult ipotent and Erythroid Progenitors Exposed to p lXY321 
St i mu l i  
p lXY321 + rEpo 
plXY321 + rEpo + Bryo 1 
. 1  nM 
. 5 nM 
1 nM 
1 0  nM 
1 00 n M  
Day 1 4  Colonies/ 4000 C D34+ Marrow Cells 
BFU-E CFU-GEMM 
expo 1 #  expo 2# expo 1 #  expo 2# 
35 ± 8 1 4  ± 4 28 ± 3 42 ± 6 
3 1  ± 4 2 1  ± 3 24 ± 4 42 ± 5 
34 ± 3 1 6  ± 1 1 7  ± 2 * 30 ± 5 
27 ± 3 1 8  ± 6 1 1  ± 5 * 23 ± 2 * 
4 ± 2 * 5 ± 2 * 6 ± 5 * 6 ± 2 *  
1 3  ± 4 * 9 ± 4  8 ± 5 * 1 3  ± 4 * 
Cells were plated in the methylcellulose medium with human serum additive in the presence 
of p lXY321 ( 1 0ng/ml) and rEpo (1 unit/ml) in conjunction with bryostatin 1 .  After 1 4  days' 
incubation, colonies were scored as described in the text. Values represent the means ± 
SD for each independent experiment performed in triplicate. One additional experiment 
yielded similar results. 
• significantly less than values for the combination of plXY32 1  + rEpo (p < .05) . 
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Table 1 0 . Effect of Bryostat in 1 on the Growth and Lineage Commitment of 
Mu lt ipotent and E rythroid Progen itors Exposed to rSCF and p lXY321 
Day 1 4  Colonies! 2000 CD34+ marrow cells 
Sti m u l i BFU-E CFU-GEMM 
rSCF+pIXY32 1 + rEpo 7 ± 4  8 ± 2  
rSCF+pIXY321 + rEpo + Bryostat in  1 
.05 nM * 7 ± 4  5 ± 0  
. 1  nM 7 ± 6  5 ± 2  
1 nM 4 ± 2  5 ± 1 
1 0  nM 0 0 
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Cells were plated i n  the presence of rSC F  ( 1 00ng/ml) , p lXY321 ( 1 0ng/ml) and rEpo ( 1  uniVml) 
in conjunction with bryostatin 1 .  After 14 days' incubation,  colonies were scored as described 
in the text. Values represent the means ± SD for three independent experiments performed 
in triplicate . * Two experiments were performed at .05 nM bryostatin 1 
D I S C U S S I O N  
Prev ious studies have demonstrated that pharmacologic manipu lations of 
P K-C by phorbol esters or  bryostati n 1 substant ia l ly en hance the abi l ity of 
C 034 + human bone marrow cel ls to form granulocyte-macrophage colonies i n  
response t o  rGM-CSF. 1 26 The present f indi ngs extend these observat ions to rlL-
3 ,  p 1 XY32 1 , and rSCF i nduced he matopoietic ce l l  p ro l i ferat ion ,  and further  
suggest that PK-C act ivity plays a critical ro le i n  determin i ng the prol iferation  and 
l i neage commitment of HGF sti mu lated early as well as committed myeloid 
progen itors. More specifical ly, the present data are consistent with a ro le for PK­
C act ivity i n  i n h ibi t ing rGM-CSF, r IL-3, p 1XY321 , and rSC F  i nduced eosi nophi l ic 
d i fferentiat ion ,  whi le promoti ng the growth of ce l ls of the neutroph i l  o r  monocyte/ 
macrophage l i neage.  This hypothesis is supported by the observat ions that: 1 )  
t h ree classes of PK-C activators exh ibit i ng different bio logical activit ies (e. g . ,  
st rong o r  weak t u m o r  promot i ng , or non-tumor  promot i ng )  showed s im i lar 
hematopoiet ic stimu lat ing effects. 2) 4 O'.-POO (a non-PK-C st i m u lati ng phorbol 
ester analog) neither enhanced growth factor- i nduced co lony format ion nor did it 
i nduce l i neage alterat ion when coadmin istered with either r 1L-3 or  p 1XY32 1 . 
Although earl ier  studies re lated the hematopoietic st imu latory capacity of 
phorbol esters to the i r  tumor promoti ng capabi l i t ies, 1 34, 1 35 the present f ind ings 
suggest a d iscordance between the two effects. For example ,  whereas POBu is  
a potent pri mary tumor  promoter, mezere i n  i s  classif ied as a second stage 
promoter i n  mouse ski n tumor assay systems, and exh ibits l itt le p rimary tumor 
promot i ng activity. 1 56 In  contrast to both of these agents, bryostat in  1 essent ia l ly 
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lacks tumor  p romoti ng act iv i ty . 1 1 8 , 1 1 9 Neverthe less ,  each PK-C activator  
potent iated colony format ion  to an equivalent degree, and produced s im i lar 
qual itative changes in colony composit ion ,  although the dose response profi le of 
these agents d iffered sign i ficant ly . These findi ngs suggest that the hematopoietic 
regu latory effects of  these compounds are not d i rect ly re lated to the i r  tumor 
promoti ng propert ies.  
The regu lation  of hematopoiesis by g rowth factors such as, IL-3 and G M­
CSF is a coord inated process i nvolv ing stimu lat ion of the prol ife ration  of more 
primit ive progen itors as wel l  as the determi nat ion of the i r  l i neage commitment.  
For  example,  the g rowth and different iat ion of ce l ls  of the eosi nophi l ic l i neage 
are regu lated by the act ions of I L-3,  G M-CSF, and I L_5.6 ,8 1 -84  Eos inoph i l ic  
colon ies  have been shown to account for  a majo r f ract ion of I L-3 and G M-CSF 
st imu lated day 1 4  CFU-G M  in both m u ri ne and human systems,  and th is  
com ponent can be further expanded by coadmin i st rat ion of  IL_5.43,83 ,84 The 
avai lable evidence i nd icates that I L-3 and G M-CSF i nduce pro l i fe rat ion  and 
commitment of more pr imit ive eosi noph i l ic progenitors ,  whereas I L-5 acts to 
support te rm i na l  d i ffere nt iat i on  of ce l l s  commi tted to t he  e o s i n o p h i l i c  
I i neage . 43 ,83 ,84 Our  fi nd i ng that PK-C activators effect ively b lock eosinoph i l ic 
d i fferentiat ion i nduced by rSCF, rGM-CSF and r1 L-3 (or p 1XY321 ) but not r IL-5, 
suggests that PK-C mediated events alte r the d i ffere nt iat ion  program of more 
pr i mit ive hematopoiet ic progen i tors that have not u ndergone an i rrevers ib le  
u n ipotent l i neage commitment .  Th is  observat ion  favors the hypothes is  that 
perturbat ions i n  the PK-C s ignal  transduct ion pathway may modu late g rowth  
factor i nduced Signals, and  together may serve to  prevent mu lt ipotent progenitor 
ce l ls from committi ng to ce l ls of the eosi noph i l ic l i neage. However, the possibi l i ty 
of selective recru itment of com mitted neutroph i l  and macrophage progenitor 
ce l ls i nto ce l l  cycle can not be ru led out as an alternative explanation for these 
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f ind ings .  
Wh i le  other i nvest igators have demonstrated that bry ostati n 1 1 25 and 
phorbo l esters 1 35 stimulate hematopoiesis through activat ion of accessory cel ls ,  
e .g . ,  by e l iciti ng the release of I L-3, G M-CSF, G-CSF and CSF- 1 , it is u n l ikely 
that this mechan i s m ,  by itse lf, cou ld be solely respo ns ib le for  the cu rre nt 
observatio ns.  For example, the use of low density, adhere nt ce l l  depleted , 
C D34 + bone marrow monon uclear ce l l  popu lations  substantial ly reduces the 
possibi l ity that s ignif icant n u m bers of residual accessory cel ls remain in the 
cu ltures. I n  addit ion ,  the resu lts from low ce l l  density cultures demonstrated that 
bryostat i n  1 cont i nued to enhance colony formatio n  ( i n  some cases) and 
modu late l i neage comm itment ( in  al l  cases) of myeloid progen itor ce l ls exposed 
to rG M-CSF, r 1L-3 or p 1XY32 1 ,  eve n when cells were plated at densities as low 
as 62 ce l ls/ml well .  These f ind ings suggest strongly that the effect of bryostat in 1 
i s  not accessory ce l l  dependent. Moreover, none of the PK-C activat ing agents 
e mployed i n  the study st imu lated colony format ion when adm i n iste red alone ,  
further  reduci ng the l i ke l ihood of  accessory cel l  mediated effects. Although 
bry ostat i n  1 by itse lf has previously been reported to support the growth of a 
l im ited n umber of co lon ies derived from progen itor cel l  e n riched populat ions, 1 23 
it i s  conceivable that d i fferences i n  ce l l  i so lat ion  and cu ltu re techn iques may 
have contributed to co lony format ion .  
Addit ional evidence suggest ing that bryostati n 1 exerts a di rect effect on  
mye lo id  progen i tor ce l l  g rowth and l i neage commitment stems  f rom the  
demonstrat ion that exogenous rSCF,  rG M-CSF, r IL-3,  rG-CSF and rCSF- 1  fai led 
to mi mic the effect of bryostat in  1 ,  part icu larly the i nh ibitory effect on eosinophi l  
development .  Specifical ly ,  these g rowth factors ,  when admin i stered alone or  i n  
various comb i nat ions ,  i nduced day 1 4  co lon ies exh ibiti ng  d ist i nct ly d i fferent 
l i neage composit i ons compared to colon ies observed when bryostat i n  1 was 
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i nc luded i n  the cultu re .  Fu rthermore ,  even when satu rat ing  leve ls  of rSCF,  
p 1XY32 1 ,  rG-CSF and rCSF- 1 were present i n  the  cu ltu res ,  b ryostat i n  1 
conti n ued to potentiate co lony format ion ,  which consisted primari ly of cel ls of 
macrophage l ineage. Fi nal ly , the observation  that the effect of bryostat i n  1 was 
not b locked by neut ral iz ing antibodies capable of abrogat i ng effects of G-CSF 
and CSF-1 released by residual accessory cel ls in the cu ltures further argues 
against accessory cel l  act ions. Together, these considerat ions suggest that PK­
C man ipu lat ions  act d i rect ly to i n f l uence hematopo iet ic proge n ito r ce l ls  
responsiveness to GM-CSF and I L-3, although the possib i l ity of autocri ne factors 
or  as yet u ndefi ned cell-ce l l  i nteract ions can not be ru led out at th is  t ime.  
Sev e ra l  ear l i e r  co m m u n icat i o n s  h ave descr ibed a cons iderab le 
heterogeneity of  I L-3 and GM-CSF receptors i n  hematopoietic cel ls .2 1  There are 
two subclasses among those receptors. 23,24 The fi rst class (class I) is specific 
for either G M-CSF or I L-3. There is no cross-b i nding between GM-CSF and I L-3 
among this subpopulat ion .  It is mainly found on  mature neutroph i l ,  which can be 
rapidly down-regu lated by PK-C act ivators such as phorbol esters. The second 
class (class I I )  is capable of b ind ing with either GM-CSF or  1 1-3, and competition  
of G M-CSF and I L-3 for  ce l l  b inding i s  bel ieved to  be  re lated to th is  receptor sub­
popu lat i o n .  Th is  class of dual  receptors i s  d i st ri buted o n  normal  myelo id 
proge n itor ce l ls  as wel l  as myelob lasts obtai ned from acute myelo id leukemia 
patients, and is not  subject to  the down-regulat ion by phorbol ester compound.24 
The dual receptor behavior may explai n ,  at least i n  part ,  the funct ional overlap 
between G M-CSF and the st ructural ly disti nct I L-3.  It may also account for the 
synerg istic act ion betwee n  these two growth factors ,  i . e . ,  the recruitment of the 
class I and class I I  receptors when both growth factors are present. p lXY321 
showed en hanced hematopoietic sti mu lati ng activity as wel l  as receptor affi n ity 
to target ce l ls compared to either I L-3 or GM-CSF. p 1XY32 1 , contai n i ng IL-3 and 
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G M-CSF domains  i n  one molecu le .  has also been shown to be more potent than 
an  equ i molar mixture of GM-CSF and IL-3 i n  stimu lat i ng co lony formation  by 
human bone marrow cel ls at subopt imal level ( less than or  equal to 5 ng/ml.48,49 
The present study demonstrates that at the saturati ng leve ls. the maximal effect 
e l icited by p lXY32 1 is .  both qual itatively and quantitatively. equivalent to. but not 
g reater than,  that el icited by the combination of native form of G M-CSF and IL-3. 
This suggests that p lXY321 may recruit and satu rate the same subpopulations of 
receptors ( i .e  . . class I and class I I receptors) as those for the nat ive GM-CSF and 
I L-3. The observat ion that . at subopt imal levels, p lXY321 demonstrates g reater 
potency in stimu lat i ng colony format ion  could be exp lai ned by prefe rent ia l  
b indi ng of p lXY321 to class I and class I I  receptors ,  possibly due to receptor 
cross- l ink i ng by th is  hybrid mo lecule at non -saturat ing  levies.  Based on th is  
data, it i s  va l id  to postu late that s igna l  events mediati ng the effects of the 
p lXY32 1 are the same as ,  o r  s im i lar to ,  those mediat ing the effects of  the native 
G M-CSF and IL-3 comb inat ion ,  and that these events are subject to PK-C 
modu lat i o n .  The resu lts f rom the present study,  i ndeed.  showed s im i lar 
e nhancing and l ineage alte rat ion effects by bryostat in  1 when either p lXY32 1  or  
G M-CSF and IL-3 was coadmin istered with bryostat in 1 .  
S C F  has been shown to have stro ng synerg i st ic  effect o n  the  
m u lti l i neage  colony formation when  adm i n i stered i n  conju nctio n  w i th  I L-3 and 
G M-CSF or p IXY32 1 5 1 . 7 1 ,73 , 74 These f ind ings i ndicate t hat SCF m ight act 
di rect ly to st imu late more primit ive progen itor cel ls or to render stem ce l ls  more 
responsive to later stage HGFs, such as IL-3,  GM-CSF, and G-CSF. Recent ly ,  
SCF has been shown to induce rap id  tyrosi ne prote in  phosphory lat i on  on 
hematopoietic ce l l  l ine ,  M07e 90 I n  th is ce l l  system .  enhanced activit ies of PLCy 
88 and c-raf ki nase were related to the i r  phosphorylat ion status.90 In  muri ne 
N FS. N 1 . N 7  and FDC-P1 ce l l  l i nes as wel l  as human TF-1 cel l  l i ne SCF were 
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found to  synerg ize with e i ther I L-3 or  Epo to  e nhance c-ra f  ki nase tyrosi ne 
phosphorylat ion and activat ion  which corre lated with cel l p ro l ife rat ion .9 1  Si nce 
PLC activity is the major physio log ical source of DG, an endogenous activator of 
P K-C,  and in v i ew of the fact that PK-C act ivat ion  modu lates tyros ine  
phosphorylat ion o f  hematopo ietic cel ls i nduced by  HGFs, 1 42 the  present f inding 
that rSCF/p IXY i nduced CFU-G M colony format ion can be further enhanced by 
b ryostati n 1 provides a further evidence ind icat ing that PK-C activity may a lso 
play a role i n  mediat ing the effect of SCF on  the g rowth and commitment of early 
p rim i t ive myeloid progen itor ce l ls .  This obse rvat ion also raises the possibi l ity 
that pharmaco logical man ipu lat i on  of PK-C activity may also modu late the 
pro l i fe rat ive capacity and l i neage commi tment  of ste m  ce l l s  or ear ly 
hematopoietic progen itor ce l ls .  However, i t  is not c lear at th is  t ime whether PK-C 
activat ion  d i rect ly modu lates SCF i nduced sig na l i ng events and, therefore, 
e nhances the recru i tment and expans ion  or sel f -renewal of stem/early 
proge n ito r cel l  populat ion ,  or ,  alternat ive ly ,  SCF mobi l izes more stem/early 
prog e n ito r ce l l s  from Go i nto the prol i fe ration  cycle and renders them more 
responsive to the dual s ignals of bryostat in 1 and other late stage HGFs such as 
I L-3 and G M-CSF. These, i n  tu rn , might induce the g rowth and commitment of 
p roge n itors exh ib i t ing less self re newal capabi l i ty and more rest ricted mu lt i ­
l i neage potent ia l .  Additional  studies wi I I  be necessary to resolve these issues 
more defi n it ively ,  part icularly in the case of primary cultures of human bone 
marrow progen itors. 
The abi l ity of bryostat i n 1 to reve rse the  i n h ibi tory effects of h i gh  
concentrat ions o f  both PDBu  and mezere i n  toward GM-CSF and I L-3 stimu lated 
cu ltu res is consistent with the results of previous studies in wh ich bryostati n 1 
was found to block other phorbol este r mediated processes such as tumor  
promotion i n  mouse skin , 1 1 8, 1 1 9 and differentiation  i nduct ion i n  human leukemia 
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cel ls . 1 20 The i nh ibit ion  of co lony format ion ,  however, could not be reversed by 
b ryostat i n  1 fo l lowing a 24 pre-exposu re to h igh  concentratio n s  of PDBu ,  
suggesting t hat i rreversib le events precludi ng colony format ion had occurred by 
t hat t ime .  Although one recent report demonst rated that phorbo l  ester and 
bryostat i n  1 exert di ffe rent effects on  various PK-C isotypes, 1 57 the basis for 
biological response d i fferences between bryostat in 1 and phorbol esters remain 
large ly u n known . 
Fo l lowing  i n i t ia l  st i mu lat i on ,  cont i nuous  exposure to PK-C activat i ng 
agents has been shown to i nduce degradat ion and perSistent down regu lation  of 
PK-C in  diverse ce l l  types. 1 58- 1 60 For example, chron ic st imu lat ion by bryostati n 
1 o r  pho rbol esters has been shown to i nduce a 90% reduct ion i n  PK-C act ivity 
in the p ro myelocytic leukemic cell l i ne H L-60. 1 53 Consequent ly ,  the regu latory 
effects of PK-C act ivat ing agents on  hematopoietic cell deve lopment might stem 
from e i ther  PK-C st i m u lat i on  or  down regu lat ion .  In contrast to lymphoid 
systems, i n  which PK-C activat ion has been shown to "pri me" cel is to respond to 
subsequently adm in i stered growth promoti ng cytok ines, 1 6 1 a 24 hour exposure 
of CD34+ myelo id progenitor cel ls to bryostat in  1 p rior  to r 1 L-3 abrogated the 
potent iat ion of co lony format ion that occurred with simu ltaneous adm in istrat ion 
of  factors.  Th is  suggests that a subpopu lati on  of hematopoiet ic progenitors 
requ i res a coord inated exposure to r1 L-3 i n  conjunct ion with PK-C activat ion i n  
o rder  to u ndergo  c lona l  expans ion .  I n  co ntrast , pre-expo s u re of ce l ls  t o  
b ryostat i n  1 cont i nued to resu lt i n  i n h ib i t ion  o f  eos inoph i l ic  d i fferent iatio n ,  
suggest ing t hat alte rat ions  i n  l i neage commitment m ight b e  related to PK-C 
down regu lat ion .  In view of this f i nd i ng , it i s  also plausib le to specu late that the 
alte rat ion  from erythro id towards myeloid l i neage l i ke that observed among 
neutro ph i l ,  macrophage and eosi noph i l  l i neages m ight be a lso caused by 
cont inuous exposure to bryostat i n  1 ,  a condit ion bel ieved to downregulate PK-C 
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activity,  i n  the presence of rSCF and p 1XY32 1 . Further  experiment i nvolv ing 
replat i ng CD34+ myeloid progenitor ce l ls pretreated by bryostat in  1 is necessary 
to solve th is  issue. 
The abi l i ty of PK-C act ivat i ng  agents to promote the g rowth of  IL-3 
dependent cel ls has been taken as evidence that the g rowth promoti ng activity 
of IL-3 is mediated through PK-C stimu lat ion . 1 62. 1 63 Although previous studies 
employing muri n e  hematopoiet ic ce l l  l i nes have demonst rated an associat ion 
between I L-3 adm in ist rat ion and PK-C cytosol to  membrane t rans locat ion , 1 29 
the  i nabi l ity to obta in  suff ic ient quantit ies of human hematopoiet ic progen itor 
cel ls for  b iochem ical dete rm i n at ions  precludes making d i rect co rre lat ions  
between  levels of  PK-C activity and specific b io logic responses i n  t h i s  system. 
N everthe less,  the f ind ing that basal levels of r 1 L-3 i nduced colony format ion 
were not reduced by cond i t ions prev ious ly shown to i nduce PK-C down 
regu lation ( i . e . ,  a 24 hr  pre-exposure to  bryostat in  1 ) , and that PK-C activat ing 
agents d id not mi mic IL-3 act ions ,  suggest that the  stim u lat ion  of h u man 
hematopoiet ic cel l  g rowth by IL-3 is not  d i rectly mediated by PK-C activation .  
I nstead, they i mp ly that PK-C act ivatio n exerts a regu latory i nf luence on  events 
i nduced by G M-CSF and IL-3. Phorbol ester compound ,  PMA,  has been 
described to i nduce seri ne and threon i ne  phosphory lat ion  of tyrosi ne  ki nases,  
wh ich  corre lates with the aug ment  of tyros ine  phosphory lat i o n  on  certai n 
i ntrace l lu lar prote in  subst rates i nduced by G M-CSF i n  the M07 hematopoiet ic 
cel l  l i ne . 1 42 It is possible that the cross-talk between PK-C and tyrosi ne ki nase 
pathways is responsib le for mediat ing  the changes observed i n  the  present 
studies s i nce IL-3 and GM-CSF i nduce rapid tyrosi ne phosphory lat ion of various 
i nt racel l u lar prote i n  substrates. 95- 1 0 1 These observat ions also suggest that the 
effects of PK-C activators on  hematopoiet ic ce l l  pro l i fe ration and d i ffe rent iat ion 
i nvolve separate, and potential ly d issociable , events. 
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P rev ious  stud ies  have suggested that bryostat i ns  are capable of  
e n hancing erythroid cOlony format ion when adm in istered i n  conjunt ion with 
eryth ropoiet in in colony form ing assays employi ng l ig ht-density, adherence­
depleted normal  h uman bone marrow ce l ls . 1 23 Addit ional  studies by these 
investigators suggested that i nd i rect, accessory ce l l  mediated effects contributed 
to th is phenomenon. 1 24 . 1 25 Specif ica l ly ,  these invest igato rs demonst rated that 
bryostat in  1 stimu lated GM-CSF and IL-3 re lease from accessory ce l ls. This may 
exp la in the discrepancy between these f ind ings and those of the present study, 
where iso lated CD34+ myeloid progenitor ce l ls  were employed. I n  the presence 
of opt imal  concentrat ions of p 1XY32 1 , rSCF and eryth ropoiet i n ,  b ryostat in 1 
i nh ibited both BFU-E and CFU-GEMM co lony format ion whi le  enhancing CFU­
GM formation .  These f ind ings suggest that bryostat in 1 ,  when adm i n istered in  
conju nct ion  with p lXY321 or  rSC F/p IXY32 1 ,  may drive early m u lt i potent 
progen ito r cel ls i nto ce l l  cyc le and i nduce com mitment toward non-eryth roid 
l ineages. A lternative ly,  bryostat in 1 m ight di rect ly i nh ibit e rythro id d i fferentiation 
and maturat ion .  To address th is  i ssue long term bone marrow cultu res and 
s i ng le  ce l l  c l on i ng stud ies  shou ld y ie ld  fu rthe r  i n format ion  about these 
processes and he lp to d ist i ngu ish between these possib i l i t ies.  These f i nd ings 
furt he r  i nd icate that P K-C activ i ty may exert d iverse modu lat i ng effects on  
hematopoietic ce l ls  of d i fferent l i neages and developmental stages, which may 
i n  tu rn depend upon dose, schedule,  and sequence considerat ions.  
I n  summary , the present f ind i ngs i ndicate that bryostat i n  1 ,  as wel l  as 
other act ivato rs of PK-C, play an i mportant role i n  regu lati ng the prol i ferative 
response and l i neage com m it ment of early progen ito r  ce l l s  or committed 
myeloid progen itor cells to rSCF, rG M-CSF, rI L-3, and p 1XY321 . Specifical ly,  the 
resu lts of the present study provide the fol lowing nove l i nsights i nto the capacity 
of bryostat in 1 ,  as we l l  as other pharmaco logic i nterventions at the level of PK-C, 
74 
to modulate the response o f  primary cultures o f  human hematopoietic progen itor 
ce l ls  to both early and late act i ng hematopoietic g rowth factors: 
1 )  B ryostat in  1 ,  as wel l  as tumor-promoting PK-C activators, potentiate the 
fo rmatio n  of com m itted myelo id progen itor ce l l  co lony by CD34+ cells i n  
response t o  r 1 L-3 and rGM-CSF. 
2 )  Bryostati n 1 a lso potentiates committed myeloid progenito r  cel l  colony 
formation ,  although to a lesser degree , i n  response to p 1XY32 1 , the combinat ion 
of the native r 1L-3 and rGM-CSF, and the combination of p lXY321 and rSCF.  
3) Bryostat in 1 blocks the i nh i bitory effect of h igh concentration of PDBu 
and mezere in  toward committed myelo id progenitors .  
4 )  Bryostat in  1 (as wel l  as other PK-C activators) se lectively st i mu late the 
g rowth  of  non-eos i noph i l ic colon ies (e .g . ,  pure and m i xed neut roph i l  and 
macrophage C FU-GM)  and i n h i bi t  the format ion  of eosi noph i l ic  colon ies in 
response to rG M-CSF,  r I L-3 , and p lXY321 as wel l  as the combinat ion of 
p lXY32 1 and rSCF. 
5) The st imu lato ry effect of b ryostat i n  1 toward neutro ph i l ic  versus 
macrophage progen i tors is dose-dependent. 
6) The i n h i bi to ry effects of bryostat i n  toward eosi noph i l ic  co lony  
formation i s  both dose and schedule dependent. 
7) The sti mu latory effects of bryostat in 1 on total co lony g rowth and the 
i nh ib itory effects on eosi nophi l ic  colony format ion appear to represent separate 
and potential ly d issociable events. 
8) The effects of bryostat in 1 on co lony formation and l i neage commitment 
of CD34+ ce l ls  exposed to rI L-3, rGM-CSF, p lXY32 1 as wel l  as the combinat ion 
of p lXY321 and rSCF,  are not the result of secondary re lease of G-CSF, CSF- 1 , 
I L-3, and GM-CSF by accessory ce l ls in the cu lture.  
9) Chron ic exposure of CD34+ cel ls to bryostat in 1 may result i n  the 
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i n hi bit ion of progen itor ce l l  commitment to e rythroid different iation .  
Co l lect ive ly ,  t hese observat ions extend upon the resu lts of  p revious  
studies demonstrat ing an  important role fo r  PK-C i n  the  regu lation o f  lymphoid 
cel l  prol iferat ion and differentiat ion , 1 64, 1 65 and provide strong evidence that th is 
enzyme is  i nvo lved i n  the control of human myelopoiesis as wel l .  
F inal ly ,  the observat ion that PK-C sti mu lat ing agents selectively i nh ibits 
rG M-CSF,  r IL-3,  and p l XY32 1 i nduced eosi noph i l i c  deve lopment takes on 
added s ign i ficance in view of rece nt reports demonst rat ing an u ndesirable 
eos inoph i l ia  resu l t ing from the in vivo admi n istrat ion of rG M-CSF or  r 1 L-3 i n  
pat ients with various hematologic d isorders?5-80 Pharmacologic i nterventions  
by  agents act ing at t he  level o f  PK-C may thus be capable of b lock ing r 1L-3 o r  
rG M-CSF induced eosi noph i l ia  in vivo, and potent ia l ly i ncreasing t he  number of 
c i rcu lat i ng  neut roph i l s and macrophag es i n  response to g rowth factor  
admin istrat ion .  The  recent i n it iat ion o f  phase I trials o f  bryostat in  1 as  a potential 
ant i-neoplastic agent may make it possible to test these hypotheses di rect ly i n  
the  near futu re . Another  imp l icat ion  for t h i s  study i s  that pharmacolog ical 
manipu lat ion of the act iv it ies of key signal transduci ng ki nases may represent a 
feasib le way to regulate the in vitro prol i fe rat ion and l i neage com mitment of 
hematopoietic stem/progenitor ce l ls exposed to HGFs, and may u lt imately prove 
usefu l in the ex vivo expansion of normal hematopoietic progen itor ce l ls .  
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